

RESEARCH ARTICLE OPEN ACCESS

Multiphysics-Driven Assembly of Biomimetic Vesicles

Timofei Solodko¹ | Ian Gimino¹ | Aastha Chandiwala¹ | Bayan Alkotoub^{2,3} | Ali Bashiri Dezfouli^{4,5} | Heiko Reith⁶ | Asjad Bakhtiar¹ | Rojda Hicsanmaz¹ | Johann Brenner⁷ | Christoph J. O. Kaiser⁷ | Elena Belli¹ | Shilpi Pandey¹ | Samuel D. Rabkin⁸ | Kornelius Nielsch^{6,9} | Gabriele Multhoff⁴ | Oliver Hayden¹ | Morteza Hasanzadeh Kafshgari^{1,4} 

¹Heinz-Nixdorf-Chair of Biomedical Electronics, School of Computation, Information and Technology & Munich Institute of Biomedical Engineering, Center for Translational Cancer Research (TranslaTUM), Technical University of Munich (TUM), Munich, Germany | ²Chair of Biological Imaging, TranslaTUM, School of Medicine and Health & School of Computation, Information and Technology, TUM, Munich, Germany | ³Institute of Biological and Medical Imaging, Bioengineering Center, Helmholtz Zentrum München, Neuherberg, Germany | ⁴Radiation Immuno-Oncology Group, TranslaTUM, TUM School of Medicine and Health, University Hospital of TUM, Munich, Germany | ⁵Department of Otolaryngology, Head and Neck Surgery, TUM School of Medicine and Health, University Hospital of TUM, Munich, Germany | ⁶Institute for Metallic Materials, Leibniz Institute for Solid State and Materials Research, Dresden, Germany | ⁷Research Group CryoEM Technology, Max Planck Institute of Biochemistry, Martinsried, Germany | ⁸Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA | ⁹Institute of Materials Science, Technische Universität Dresden, Dresden, Germany

Correspondence: Morteza Hasanzadeh Kafshgari (morteza.kafshgari@tum.de)

Received: 23 September 2025 | **Revised:** 14 January 2026 | **Accepted:** 15 January 2026

Keywords: cell membranes | extracellular vesicles | microfluidic platforms | multiphysics

ABSTRACT

Artificial extracellular vesicles (AEVs) are programmable, biomimetic materials that combine the structural and biological complexity of naturally secreted extracellular vesicles (NEVs) with the design flexibility of synthetic nanomaterials. A multiphysics-driven microfluidics is developed to efficiently integrate the nanoknife-assisted membrane rupture with flow dynamics and acoustothermal modulation for the reproducible, high-yield, scalable, and standardized production of AEVs. Compared to empirical mechanical processes, this integrated microfluidic workflow, which exploits physical and biological insights for EV production, enables multiphysics-based predictions for a precise control of material inputs, flow dynamics, and cell-knife interactions within the channel. The biomimetic AEVs developed through this integrated, optimized single-flow platform, with a sustained and efficient therapeutic encapsulation process, preserve native protein architectures to conduct biomimetic mechanisms of immune modulation and homologous targeting. The standardizable microfluidic platform paves the way for a structure–process–function design strategy, enabling the formation of scalable, adaptive biomaterials for the development of bioinspired interfacial engineering and biomedicine.

1 | Introduction

Naturally secreted extracellular vesicles (NEVs) are nanoscale membrane-bound structures that mediate intercellular communication, immune regulation, and molecular transport. The original composition of proteins and lipids in isolated NEVs is biocompatible and inherently has precise targeting potential,

making them highly interesting for biomedical applications [1–4]. However, NEVs' low yield, as well as compositional and batch-to-batch variability, prevent standardization and transition to applications [5, 6].

Artificial extracellular vesicles (AEVs), derived from cell membranes, are a promising biomimetic soft material, coupling

Timofei Solodko, Ian Gimino and Aastha Chandiwala contributed equally to this work.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2026 The Author(s). *Advanced Materials* published by Wiley-VCH GmbH

the complexity and functionality of NEVs with the tunable properties of synthetic nanocarriers. AEVs, unlike e.g., liposomes or solid lipid nanoparticles, inherit their structural and functional properties from the original cell membrane [7–9]. Nevertheless, biomimetic AEVs with their batch-to-batch variability trigger random cellular signaling mechanisms, biocompatibility, and immunomodulatory responses [10]. AEV manufacturing methods employ various mechanical techniques, but these have limitations in terms of reproducibility and control over vesicular size, membrane functionality, and therapeutic encapsulation [5, 11–14]. The possible capabilities of mechanically formulated AEVs, which vary in their production and characteristics, cannot be fully utilized as standardized, programmable biomimetic soft materials and bio-interfaces.

By contrast, standardized microfluidics is a powerful alternative to manual extrusion or ultrasonication and remarkably augments EV scalability and reproducibility [15–19]. While promising, many microfluidic workflows for AEV production are still based on trial-and-error evidence due to the complex and random mechanisms, e.g., related to membrane rupture, lipid bilayer fragmentation, reformation of lipid fragments into stable vesicles, and preserved functionality of membrane proteins, as well as adjustable encapsulation of a wide range of cargos. Given ongoing developments, a recent fluidic vortex transport design, for example, has been introduced to enlarge vesicle secretion, highlighting the potential of hydrodynamics for scalable EV manufacturing [20]. However, therapeutic loading methods within an engineered platform often require more complex biochemical manipulations, altering the original vesicle functionality [21]. Therefore, a cell-type-independent, scalable, high-yield formulation of therapeutic-loaded biomimetic EVs, e.g., with mechanistic uncertainties and variability in composition, functional bioactivity, and immunomodulatory features, hinders trustworthy reproducibility and translational potential.

To enable off-the-shelf, reproducible, and highly efficient assembly of AEVs, a multiphysics-integrated microfluidic platform is developed by taking advantage of biophysical characterizations and functionalities of cell membranes. In contrast to trial-and-error approaches, this integrated microfluidic platform tunes physical and flow dynamic properties to transform EV production into a predictable materials design. This multiphysics-driven microfluidic device enhances the formation of biomimetic functional AEVs through a well-controlled mechanism by combining nanoknife-assisted membrane rupture, herringbone (HB)-induced chaotic mixing, and acoustothermal modulation in a single flow-optimized system, improving production efficiency and in situ encapsulation of a wide range of therapeutics. The formulated biomimetic AEVs in this microfluidic platform preserve the original cell membrane properties, retaining similar immune modulation and homologous targeting compared to the isolated NEVs. The generalized and standardized design principle, which enables controlled multiphysics in microfluidics for the formulation of cellular membrane-based soft matter, positions functional AEVs as a programmable interface for a wide range of biomedical and translational applications.

2 | Results and Discussion

2.1 | Assembly of AEV-Forming μ -Chips

To formulate biomimetic AEVs, an integrable, standardizable μ -chip embedding an array of sharp blades (knife- μ -chip) [19] was developed by optimizing the channel geometry by taking advantage of enhanced fluid dynamics and particle behavior in a parabolic laminar flow (Reynolds number (Re) \approx 26.67; flow rate: 2 μ L/s; channel height: 50 μ m to prevent potential clogging) (Figure 1a). The simulations with COMSOL Multiphysics indicated that particles floating in an aqueous flow (with phosphate buffer properties) mainly stay close to the center of the channel, due to the dominant drag and lift forces (Figure 1b; Note S1 and Figure S1). The flow conditions revealed increased pressure and shear rates on the blade surfaces compared to those in the flat channel. The systematic variation of knife geometry, e.g., total knife width (W_T), spacing (top gap), and undercut (blade size), is then studied to assess their effects on flow characteristics and particle–knife interactions. These different studied channel configurations produced no significant changes in the flow patterns around the knives and had a limited impact on the streamlines (Figure S2a). The designed narrower channels, for example, show an ability to increase localized shear rates, whereas wider knife geometries reduced stress magnitudes (Figure S2b). Additionally, the wider knives improved particle–knife interactions for smaller particles (5 μ m in diameter). The shear rate and flow pressure can also be reduced by increasing the undercut in narrower knives (W_T 50 μ m).

Through the simulation, for example, the wide channel (200 μ m) with a 1 μ m undercut and 15 μ m spacing (top gap) resulted in 26% particle–knife interaction for large (15 μ m) particles; however, with the lowest shear rate (0.42×10^5 1/s). The interaction in the narrower channel (50 μ m) yielded 24% with 10 μ m particles, but showed a higher shear rate (1.69×10^5 1/s), although clogging became a concern at this width. Considering the average particle size of 10 μ m, the optimal design (W_T 100 μ m; spacing \sim 15 μ m; undercut 0.5 μ m) balanced interaction (\sim 10%) with favorable shear rate (0.83×10^5 1/s) and pressure (0.175 kPa) at the center of the channel, as shown in Figure 1c and Figure S2c. Compared to the flat channel, the knife- μ -chip can achieve a higher shear rate without excessive pressure buildup, mitigating the risk of back pressure or leakage. High-shear zones near knife edges increase the likelihood of colliding efficiently, which is essential for inducing membrane rupture (Figure 1d; Note S1.1). Modulating shear at the microscale, taking advantage of structure–function relationships in soft material generation, likely facilitates membrane rupture and lipid bilayer fragmentation. A clog-free knife- μ -chip with an estimated interaction of 10% was thus fabricated using these optimized parameters (W_T = 100 μ m; spacing \sim 15 μ m; undercut 0.5 μ m; \approx 500 knives/cm over a 2 cm array) (Figure 1e), facilitating potential cell–knife interactions required for the AEV production at scale.

Despite these optimizations of the channel flow dynamics, most floating particles follow the central streamline, experiencing the dominant drag and lift forces, which results in limited particle–knife interaction (max. 26% for larger particles). Positioning the




FIGURE 1 | (a) Representative workflow of the knife- μ -chip for rupturing the floating cells and scale-up production of therapeutic-loaded biomimetic AEVs. (b) The knife array's optimized geometries (knife width, W_T), knife spacing within the array, and undercut on the particle (10 μ m in diameter) trajectory, and (c) the impact on flow parameters (flow pressure and shear rate), and particle-knife interaction of different-sized particles (circle: 5 μ m, triangle: 10 μ m, and diamond: 15 μ m). The simulation results and details of all parameters studied in the designed knife- μ -chips are shown in Figure S2. (d) Schematic of the optimized geometries of the knife array based on the simulations predicting the optimal interactions with a reasonably high shear rate. (e) Representative micrographs of the fabricated Si_3N_4 knife array with an undercut of 0.5 μ m. (f–h) To enhance particle-knife interaction in the knife- μ -chip (Movie S1), different well-assembled HB patterns on the PDMS upper constraint were implemented to improve fluid mixing by introducing controlled disturbances while maintaining laminar flow. Accordingly, the simple flat PDMS channels were replaced with sophisticated HB-integrated knife- μ -chips (hink $^{\theta}$ - μ -chips) to improve the yield of AEV formulations. Various HB patterns with some variable factors, such as bone gap (W_{HB}), width (G_{HB}), and height (H_{HB}), were designed and simulated at different angles to optimize interaction by studying their impact on flow dynamics and particle trajectories in hink $^{\theta}$ - μ -chips (Figures S4–S7). (f–i) The schematic representation of the upper-constraint HB configuration of SYM45 $^{\circ}$ embedded on the knife array, and (f–ii) The estimated effects of HB heights and spacings (G_{HB} : 10 and 20 μ m) of SYM45 $^{\circ}$ HB patterns on the flow pressure, shear rate, and

knife array at the center of the channel also did not enhance the particle-knife interaction, shown in the simulation, as particles typically encounter the first blade and are diverted thereafter, resulting in an elevated shear-based rupture (Figure S2d). An enhanced AEV yield was thus achieved primarily by increasing cell concentration (e.g., $> 10^7$ cells/mL) and extending the recirculation period [19]. To further increase particle-knife interaction, HB patterns were then embedded into the upper constraint layer of the PDMS (polydimethylsiloxane) channel, disrupting laminar flow while maintaining structural integrity [22, 23].

To study flow behavior and particle dynamics throughout HB-embedded μ -chips, symmetric HB configurations with 45° and 60° angles (hink^{SYM45}- μ -chip and hink^{SYM60}- μ -chip, respectively) were then designed and simulated with varying bone spacing (G_{HB}), width (W_{HB}), and height (H_{HB}) (Figure 1f,g; Note S1.2). On the one hand, hink^{SYM45}- μ -chip (W_{HB} 10 μ m; G_{HB} 10 μ m; H_{HB} 35 μ m) achieved 48% interaction, a shear rate of 2.8×10^5 1/s, pressure of 2.5 kPa, and flow velocity ≥ 1 m/s (Figure 1f(i); Figure S4a,b). For example, increasing G_{HB} to 20 μ m (Figure 1f(ii); Figure S4c) further increased interaction (64%) and shear rate (3.28×10^5 1/s); however, this configuration likely led to potential leakage and back pressure (3.6 kPa). SYM45° patterns redirected flow toward the blades, maximizing first-blade interaction and altering downstream flow and other flow parameters (Figure 1f(iii); Figure S4d,e). The optimized SYM45° chip enhanced knife interaction 4.8-fold (compared to knife- μ -chip) and was successfully fabricated in upper-constrain PDMS (Figure 1f(iv)). On the other hand, hink^{SYM60}- μ -chip initially yielded 38% interaction (G_{HB} 10 μ m) but was increased up to 78% with G_{HB} 20 μ m, shear rate 3.47×10^5 1/s, and pressure 3.6 kPa (Figure 1g(i,ii); Figure S5a-c). Although low pressures (Figure 1g(iii); Figure S5d,e), the optimized SYM60° chip (G_{HB} 10 μ m) achieved a 3.8-fold increase in interaction (compared to the knife- μ -chip) due to its higher velocity than the straight channel without HB configurations, while also resulting in less buildup pressure and was fabricated (Figure 1g(iv)).

In contrast, an asymmetric staggered HB design (hink^{ST45}- μ -chip) introduced chaotic advection (Figure 1h; Figure S6a) with an optimized configuration (G_{HB} 10 μ m; H_{HB} 35 μ m), achieving an interaction of 64% and shear rate of 3.26×10^5 1/s at 3.4 kPa (Figure 1h(i); Figure S6b). This configuration provided uniform shear distribution and effective particle redirection flow dynamics parameters compared to other HB configurations (Figure S7). With G_{HB} 20 μ m (Figure 1h(ii); Figure S6c), the shear distribution shifted, but the interaction remained the same, outperforming symmetric designs by a margin of ~ 2 -fold. The ST45° flow generated velocities of ~ 0.6 m/s and distinct streamlines and

flow dynamics facilitating particle-knife interactions over other configurations (Figure 1h(iii); Figure S6d,e), and was fabricated in PDMS (Figure 1h(iv)). While upper constraints demonstrated increased stress, the sharp knives likely remain most effective at rupturing viscoelastic cells. Although tightly packed HB channels (G_{HB} 0 μ m) could achieve 54% interaction (11.44 kPa, 3.8×10^5 1/s) as shown in Figure S8a, increasing risk of clogging and leakage at high cell densities. The chaotic streamlines and transient channel height reduction were therefore generated by HB configurations to enhance particle-knife contact, allowing for fine control over shear magnitudes and spatial stress distribution (Figure S8b), which likely tunes cellular rupture dynamics and lipid fragmentation.

2.2 | Performance Metrics of AEV-Forming μ -Chips

To evaluate how efficiently functional AEVs can be produced by taking advantage of numerically modified designs, we systematically studied hink^o- μ -chips (θ : SYM45°, SYM60°, and ST45°) under controlled flow and shear stress conditions (Figure 2a). A peristaltic pump was used to circulate 2 mL of a 4 million-cell suspension (2 million cells per mL) at a rate of 2 μ L/s for 60 min, promoting efficient cell rupture (Figure 2b). This setup, optimized for low flow rate, pressure buildup, and cell input, improved the previous system, which used a higher flow rate (~ 17 μ L/s) and required 11 manual re-circulations of a denser suspension (10 million cells/mL) [19]. In agreement with the numerical simulation, the HB-integrated μ -chips exhibited higher U87 cell rupture rates compared to the standard knife- μ -chip (Figure 2c). The ultrafiltration recovery then confirmed that U87-AEV yields were higher in HB-patterned chips. For example, ST45° produced 5.17×10^9 AEVs/million cells, SYM60° yielded 2.8×10^9 , and SYM45° yielded 2.7×10^9 , whereas the knife- μ -chip produced only 2.1×10^9 AEVs/million cells (Figure 2d). Across configurations (following differential centrifugation and multistep filtration), the formed U87-AEVs, with less variability between batches, exhibited narrow size distributions (< 150 nm) by forming stable lipid fragments (Figure 2e-g; Note S2 and Figure S9). Additionally, as the first control, Raji-derived AEVs (Raji-AEVs) were formed using hink^{ST45}- μ -chips and recovered at a rate of 7×10^9 per million cells (protein content: 30 μ g/million cells), compared to 3.7×10^9 (protein content: 25 μ g/million cells) using knife- μ -chips (Figure 2h,i). The average diameter of Raji-AEVs remained similar regardless of whether they were produced using hink^{ST45} or knife- μ -chips (Figure 2j,k). Furthermore, the isolated primary human red blood cells (RBCs), as the other control cell type (7 million per mL, 2 mL total volume without

particle-knife interaction (Figure S4). (f-iii) The particle trajectory (10 μ m in diameter) in the hink^{SYM45}- μ -chip with optimized geometries (Movie S2). (f-iv) Following the optimized parameters, the representative micrograph of the mold with SYM45° HB-patterned PDMS channel. (g-i) The schematic representation of the upper-constraint HB configuration of SYM60° embedded on the knife array, and (g-ii) the estimated impacts of HB heights and spacings (G_{HB} : 10 and 20 μ m) of SYM60° HB patterns on the flow pressure, shear rate, and particle-knife interaction (Figure S5). (g-iii) The representative particle (10 μ m in diameter) trajectory in the hink^{SYM60}- μ -chip with the optimized geometries (Movie S3). (g-iv) The representative micrograph of the mold with SYM60° HB-patterned PDMS channel by following the optimized parameters. (h-i) The schematic representation of the upper-constraint HB configuration of ST45° embedded on the knife array, and (h-ii) The estimated effects of HB heights and spacing (G_{HB} : 10 and 20 μ m) of ST45° HB patterns on the flow pressure, shear rate, and particle-knife interaction (Figure S6). (h-iii) The representative particle (10 μ m in diameter) trajectory in the hink^{ST45}- μ -chip with the optimized geometries (Movie S4). (h-iv) Following the optimized parameters, the representative micrograph of the mold with ST45° HB-patterned PDMS channel.




FIGURE 2 | The representative (a) design of HB patterns (W_{HB} : 10 μ m, G_{HB} : 10 μ m with θ : SYM45°, SYM60°, and ST45°) and (b) schematic of assembled hink⁰- μ -chips connected to a peristaltic pump circulating the floating cells. (c) The U87 cell rupture efficiency in the μ -chips (θ : SYM45°, SYM60°, and ST45°), cycling the floating U87 cells for 60 min (4 million cells, 2 mL). The U87-AEVs produced in knife- and hink⁰- μ -chips, (d) AEV count per million cells (one-way ANOVA with the Tukey correction with a normal distribution), (e) average diameter of AEVs, (f) representative size distribution, and (g) cryo-electron microscopy (cryo-EM) micrograph of U87-AEVs. Raji-AEVs produced in knife- and hink^{ST45}- μ -chips, (h) yield per million cells, (i) protein content, (j) mean diameter, and (k) size distribution. (l) The representative analysis of PI uptake in U87 cells indicates membrane rupture during AEV formation in knife- and hink^{ST45}- μ -chips, with greater disruption in ST45° channels. (m) The fluidic phenomena in the cell-knife interaction and cell rupture, illustrating the estimated maximum net forces on particles (10 μ m diameter, representing the properties of a floating cell) within μ -chips. (n) The net force magnitudes on individual cells along the channel (normalized length) in hink⁰- μ -chips compared to knife- μ -chips without HB structures. (o) The calculated shear stress on the knife in different spots of hink⁰- and knife- μ -chips. All bar graphs plot data as means \pm SD of ≥ 5 independent experiments.

any platelets and other blood components), e.g., different from nucleated cancer cells due to their nucleus-free, organelle-poor, and highly deformable structure [24, 25], were run with hink^{ST45}- μ -chips, and showed a ≥ 3 -fold increase in AEV production yield compared to the knife- μ -chips (Figure S10). It is likely that the hink^{ST45}- μ -chip with HB mixing features, compared to the knife- μ -chips, enhances the fluid dynamics and mechanical interactions of the floating biconcave disc-shaped RBCs by pushing them toward the knife array under high vorticity and shear stress.

Potential impurities might stem from technique limitations (not eliminating cellular debris or co-isolated proteins) [26, 27]. Gradient density ultracentrifugation (Figure S11a), an alternative to ultrafiltration, yielded higher AEV recovery (Figure S11b), with hink^{ST45}- μ -chips forming 1.1×10^{10} AEVs/million cells compared to 7×10^9 in the knife- μ -chip. The AEVs collected from hink^{ST45}- μ -chips also showed a higher protein content, reaching ~ 20 μ g per million cells (Figure S11c). AEV size distributions (Figure S11d,e) were similar between ultracentrifugation and ultrafiltration, and the efficiency of microfluidic-based AEV assembly. In addition, processing GFP-expressing U87 cells with HB-integrated μ -chips increased GFP-AEV production by ~ 1.4 -fold, supporting the role of HB patterns in enhancing membrane rupture and efficient AEV formation (Figure S12a). Propidium iodide (PI) staining during cell rupture confirmed that the ST45° HB chip performed more efficiently than the knife- μ -chip in promoting membrane disruption (Figure 2l). While HB configurations were found to likely increase the probability of cell damage and AEV production yield, the actual rupture efficiency depends on complex and variable cell-knife collision dynamics. The refined microscale flow and stress fields likely enable deterministic control over vesicle fragmentation, a key factor in the formation of programmable soft materials. Due to the multistep washing process, AEV production remained consistent regardless of the incubation media (PBS, exosome-depleted, and standard complete medium with 10% FCS) before the rupture process (Figure S12b). Washing cells before rupture minimized contamination from NEVs and residual proteins in the culture medium. While EVs can be readily isolated, the critical challenge lies in their quantity and quality, making recovery and purification controversial. Although different purification approaches may yield different protein contents due to the presence of free-floating or non-discarded proteins, the measurement of pure protein concentrations (with no particles) likely reveals no interference with particle counts (Figure S12c). Channels without knives were tested, with floating cells also experiencing shear stress (calculated ~ 50 Pa) in channels without knives or herringbone structures, producing fewer AEVs (1.4×10^9 particles/million cells) than hink^{ST45}- μ -chips with no knives (2.5×10^9 particles/million cells, Figure S12d). Unlike knife- μ -chips, which require more resources, extended circulation (≥ 120 min), and limited cell-knife interaction, hink^{ST45}- μ -chips allow faster production with reduced input requirements (Figure S12e).

Through the numerical analysis, the maximum forces performed by the fluid on the cells approximated as point masses of 68.3 nN (SYM45°), 99.3 nN (SYM60°), and 36.1 nN (ST45°), compared to 1.73 nN in the standard knife- μ -chip (Figure 2m,n), and indicated distinct force spikes at ST45° pattern entry and exit points (Figure S13a). Accordingly, the HB configurations are able to introduce localized flow disturbances, improving cell-knife interactions and

increasing the likelihood of mechanical stress and rupture in the channel. All designed HB patterns calculated an initial force peak followed by a second rise, compared to standard knife- μ -chips (without HB), with no changes in the force vector. The floating particles in hink^{ST45}- μ -chips show particular force vector changes, indicating dynamic, directionally varying mechanical interactions induced by HB structures. These HB patterns, altered by $Re \approx 34.78$ at a flow rate of 2 μ L/s, especially ST45°, likely direct the force vectors of non-interacting particles toward the blades (Figure S13b). The calculated shear stress on the knives also exceeded 800 Pa under HB patterns, which is higher than the ~ 33 Pa observed in standard μ -chips (Figure 2o; Figures S2 and S14). The high shear stress in the hink^{ST45}- μ -chip likely contributes to membrane rupture by stretching cell membranes upon the cell-knife interaction [28].

The shear stress is one of the well-known mechanical forces that transiently modulate membrane permeability and enhance NEV release [15]. Therefore, combining high shear stress and sharp knife geometry (along with variations in each cell stiffness, driven by nucleus-to-cytoplasm ratio and cytoskeletal organization) likely impacts the rupture rate. The floating U87 cells, with Young's modulus of ~ 0.651 kPa and relaxation time of ~ 0.54 min, likely experience deformation during interactions with the knife, HB patterns, or channel walls, exceeding the compressive stress (~ 12.4 kPa) and leading to cell rupture [29, 30]. Moreover, these floating cells that are pushed toward the knives could momentarily touch and stick to the blades; a short pause under high shear stress (≥ 20 kPa) might lead to a sudden membrane damage, likely rupture, as demonstrated through fluid–structure interaction (FSI) analysis vs. knife- μ -chip (Figures S15 and S16). The intense compressive forces from collisions and shear stresses can make these rupture phenomena impactful. As a result, the optimized hink^{ST45}- μ -chips (θ : SYM45°, SYM60°, and ST45°) compared to knife- μ -chips are able to manage particle–knife interaction during application, enhance shear, mitigate mechanical forces on the floating cells, and improve flow stability, improving yield while minimizing clogging and pressure-induced channel failure. The implemented assumptions considered fixed contact constraints between the cell and the knife, a 2D velocity profile (neglecting transverse heat flux effects), a ramped inlet velocity to enhance numerical stability, and restricted deformation due to meshing limitations in the FSI COMSOL Multiphysics model. These conditions are designed to simulate experimental observations in which floating cells interact with the knives, and subsequently, some cells adhere to the knives, rupture suddenly, and form a ‘carpet’ across neighboring structures (Figure S17, Movies S5 and S6). The interacting cells with knives are unlikely to remain intact in the channel due to the high shear stress, which prevents clogging of the channel in the hink^{ST45}- μ -chip.

2.3 | Therapeutic-Encapsulating AEVs

The in situ encapsulation of doxorubicin hydrochloride (DOX), as a proof-of-concept drug, during AEV formulation was evaluated using μ -chip platforms (Figure 3a). A suspension of U87 cells (1×10^6 cells/mL) was incubated with DOX (20 μ M) and continuously processed through μ -chips for 60 min, enabling real-time formulation of DOX-loaded AEVs (DOX-AEVs). Encapsulation efficiencies were higher in the hink^{ST45}- μ -chips compared to




FIGURE 3 | (a) The representative schematic of forming DOX-AEVs using a knife- μ -chip connected to a peristaltic pump, which circulates the floating U87 cells (1 million/mL, 60 min) with DOX (10 μ M) for 60 min. (b) The DOX loading amount (μ g) into AEVs using knife- μ -chip and hink^{ST45}- μ -chip (Lognormal distribution analyzed by Mann-Whitney test). (c) The measured encapsulation efficiency (the loaded amount of DOX into AEVs compared to the initial amount of DOX in the solution) shows a higher loading level for the formulated AEVs using the hink^{ST45}- μ -chip (normal distribution analyzed by an unpaired two-tailed *t*-test). (d) The size distribution (mean diameter) of DOX-AEVs formulated using the knife- μ -chip and the hink^{ST45}- μ -chip. (e) The representative FACS analysis of DOX-AEVs compared to empty AEVs. (f) The schematics of forming DOX-AEVs using acoustothermal-integrated μ -chips connected to a peristaltic pump, circulating the floating U87 cells (1 million/mL, 60 min circulation) with DOX (10 μ M) for 60 min. (g) The total acoustic pressure (theoretical) was calculated by simulating the piezoelectric transducer at the actual frequency of 9.73 MHz (Movie S7). (h) The representative simplified 2D simulation of traveling acoustic waves generated by the frequency of 9.73 MHz of the piezoelectric transducer at the applied 60 Vpp (assumptions: considering a uniform distribution of the acoustic pressure at the small section of the center of the transducer and channel, an acoustic wave propagation without the attenuation and reflection from the inner boundaries, and a perfect piezoelectric transducer materials and devices). (i) The simulated temperature profile of the surface of the piezoelectric transducer (9.73 MHz) with variable applicable Vpp at room temperature (RT). (j) The representative simulation of the temperature profile of acoustothermal-integrated μ -chips at the constant frequency of 9.73 MHz and 60 Vpp. (k) The effect of flow rate on the channel's temperature profile at the constant frequency of 9.73 MHz and 60 Vpp, and (l) calculated temperature profile of the channel's flow (2 μ L/s). The temperature profile of the channel was calculated based on the concentrated heat flow generated within the multilayer structure, comprising the transducer, a glycerol coupling layer, and a silicon nitride wafer, rather than from direct acoustic heating of the fluid. The representative thermal images of (m) acoustothermal-integrated μ -chip (shown by a dashed rectangle), (n) its calculated temperature profile of the PDMS block (4 mm above the knife array), and (o) the sample reservoir at the end of the process (60 min). The entire formulation process was performed in a cold room refrigerator (5°C). (p) The DOX loading ratio into the formulated AEVs using acoustothermal-integrated μ -chips (constant frequency of 9.73 MHz and 60 Vpp, 60 min) based on the μ -chips without applying acoustics (standard two-tailed *t*-tests with a normal distribution). (q) The protein content analysis of the formulated AEVs using acoustothermal-integrated μ -chips at a constant frequency of 9.73 MHz and 60 Vpp for 60 min (one-way ANOVA with the Tukey correction with a normal distribution). All bar graphs plot data as means \pm SD of at least 3 independent experiments.

knife- μ -chips (Figure 3b,c). The average diameter of the DOX-AEVs increased slightly (~ 134 nm), particularly for those generated in hink^{ST45}- μ -chips, compared to unloaded AEVs (~ 129 nm) (Figure 3d). Flow cytometry further confirmed the drug encapsulation, as evidenced by a rightward shift in the fluorescence signal for DOX-AEVs (Figure 3e). The disrupted streamline patterns in hink^{ST45}- μ -chips, calculated by numerical simulation, enhanced particle-knife interactions and mixing effects within this microscale mechanical environment, potentially explaining the improved loading efficiency of passive carriers and flow-responsive soft materials.

To further improve in situ encapsulation, acoustothermal-integrated μ -chips (with and without ST45°) were designed by utilizing bulk acoustic pressure generated from a piezoelectric transducer (Figure 3f). At the peak frequency (9.73 MHz; Note S3 and Figure S18), bulk acoustic pressure with a sinc-function surface distribution was generated (Figure 3g). This bulk acoustic pressure in the simulation highlights alternating pressure nodes and antinodes forming across the channel (Figure 3h), which was likely ineffective for altering the particle trajectory at high flow rates (e.g., $2 \mu\text{L/s}$ used for producing AEVs). However, the acoustic-based vibrations also led to a temperature rise on the embedded transducer (Figure 3i), which can be modulated by increasing the peak-to-peak voltage (V_{pp}). The calculated heat flux also indicated a temperature rise with increasing V_{pp} at a constant flow rate (Figure 3j–l) in the acoustothermal-integrated μ -chip, modulating lipid bilayer fluidity and permeability.

As a control, the simulation, e.g., of a heater providing constant heating beneath the μ -chips at 40°C and 60°C (Figure 4; Figure S19), compared to the acoustothermal approach, shows a uniform temperature profile across the channel, particularly on the knives. Compared to the heater-integrated μ -chip (Figure 4a–d), the temperature profile of the acoustothermal integrated μ -chip exhibits a bell-shaped distribution with a localized thermal peak (Figure 3k), which likely prevents prolonged constant heat exposure to the floating cells and formulated AEVs. This optimized acoustothermal phenomenon provides spatially localized membrane fluidization and promotes therapeutic permeation. In addition, at lower flow rates, acoustothermal phenomena are effective but also risk clogging; however, the highest temperature point across the acoustothermal channel shifts downstream as the flow rate increases. Compared to the heater-integrated μ -chip (Figure 4e), the thermal images of the acoustothermal-integrated μ -chip (after 60 min of processing) depicted a temperature of $\sim 36^\circ\text{C}$ on the surface of PDMS (Figure 3m), fairly close to the calculated temperature profile (Figure 3n) and $\sim 5^\circ\text{C}$ in the sample reservoir (Figures 3o and 4f). Despite the intricate mechanisms of bulk acoustics, placing μ -chips on the transducer with optimized parameters improved the DOX encapsulation into the formulated AEVs compared to those without acoustothermal effects (Figure 3p) at the operational ice-cold flow rate (sample reservoir and environment maintained at 5°C). No significant effect of the acoustothermal phenomena was observed on the formulation yield of the AEVs (Figure 3q). Accordingly, increasing the μ -chip temperature to 60°C via external heating improved drug encapsulation, although this approach did not affect the overall AEV production yield (Figure 4g,h). In addition, ultrasonication of cells in an ice-cold container (Figure 4i–l), resulted in comparable encapsulation rates of $\sim 13\%$ (1 min

of ultrasonication) and $\sim 22\%$ (5 min of ultrasonication), but likely compromised vesicle integrity [31, 32]. The flow vorticity and shear stress on the optimized knife array, tuned by HB configurations, as well as the optimized acoustic pressure, which triggers moderate temperature gradients in the flow (Figure S20), can control the formation of high-yield membrane fragmentation and transient membrane permeability, thereby improving cargo loading efficiency and providing a stable encapsulation (Figure S21). The acoustothermal-integrated microfluidic device enabled precise thermal modulation of the lipid bilayer, resulting in enhanced encapsulation efficiency through the synergistic effects of mechanical and thermal inputs. The acoustothermal integrated shear stress strategy, as an alternative physical method compared with protein-lipid engineering approaches [21], enhances encapsulation while preserving the structural stability and functional integrity of AEVs, potentially simplifying large-scale production of functional, programmable AEVs from diverse cell sources.

2.4 | Bioinspired Performance of Functional AEVs

To evaluate the biomimetic functionality, the formulated AEVs produced through the optimized μ -chips were detected by the presence of common tetraspanins' EV markers (CD9, CD63, CD81) on their surface, comparable to the original U87 cells and isolated U87-NEVs as determined by flow cytometry (Figure 5a). Western blot analysis (Figure 5b) showed the presence of cytosolic (CD9, HSP70, TSG101) but not endoplasmic reticulum proteins (e.g., Calnexin and GRP94) in the AEVs compared to whole cell lysates of U87 cells. In addition, it is evident that protein coronas inevitably form on vesicle surfaces under physiological conditions, particularly in vivo, potentially altering surface functionality, receptor accessibility, and recognition (Figure S22) [33, 34]. The preserved functional integrity of the AEV surface molecules was confirmed using microscale thermophoresis (Figure S23a), which demonstrated the presence, e.g., of PD-L1 (K_D 10.03 nM) on the surface of the AEVs by a high-affinity binding (nanomolar range) of anti-PD-L1 monoclonal antibodies (mAbs) [35]. As an orthogonal control, Raji-AEVs also indicated the expression of common EV markers (Figure 5c,d) and high affinity toward monoclonal anti-cmHsp70.1 Abs (Figure S23b). The protein flipping that likely occurs during mechanical rupturing processes for the AEV formulation is inevitable; however, the strong binding affinities indicate that their retained molecular recognition capabilities (e.g., not all inverted, buried, or denatured epitopes) are central to the design of functional, biologically active soft materials. In addition, cryo-EM micrographs of the formulated AEVs (Figure 5e; Figures S24 and S25) present an intact lipid bilayer equipped with proteins, whether placed on the outer and luminal membrane sides of the AEVs. Furthermore, when stored at 5°C for up to 42 days, AEVs remained stable in terms of particle counts during the first week. A moderate increase was then observed by week 3, followed by a gradual reduction. While the average peak size remained stable, the overall size distribution shifted slightly, but non-significantly, over time (Figure 5f–h) due to various biophysical effects that occurred during prolonged incubation [36].

To further study the biological responses of activated human immune cells and the biomimetic features of the freshly formulated U87-AEVs, we evaluated their effects on primary NK




FIGURE 4 | (a) The representative schematic of forming DOX-AEVs (U87-derived) using heater-integrated μ -chips connected to a peristaltic pump circulating the floating U87 cells (1 million/mL, 60 min circulation) with DOX (10 μM). The representative simulation of (b) the temperature profile of heater-integrated μ -chips at the constant temperature (60 °C), and (c) the calculated temperature profile of the flow (2 $\mu\text{L/s}$) in the channel. (d) The effect of flow rate on the temperature profile and heat transfer of the channel (2 cm) related to heater-integrated μ -chips at the constant temperature of 60 °C. The representative thermal images of (e) heater-integrated μ -chips (shown by a dashed rectangle) and (f) the sample reservoir at the end of the process (60 min). The entire formulation process was performed at 5 °C. (g) The DOX loading ratio into the formulated U87-AEVs using heater-integrated μ -chips (60 °C for 60 min) compared to the μ -chips without applying temperature (standard two-tailed *t*-tests with a normal distribution). (h) The particle count analysis of the formulated U87-AEVs using heater-integrated μ -chips at a constant temperature of 60 °C for 60 min (standard two-tailed *t*-tests with a normal distribution). (i) The representative schematic shows the DOX-loading procedure using ultrasonication to estimate and compare the DOX encapsulation rate in AEVs in situ. An intensive cell rupturing approach (control study) was employed using ultrasonication (30 kHz frequency, total duration of 1 and 5 min; 0.5 s of sonication and 0.5 s pause, 100% amplitude, performed in an ice-cold box at 5 °C). (j) The DOX loading ratio into the formulated U87-AEVs using ultrasonication (one-way ANOVA with a normal distribution) into a mixture of U87 cells (1 million per mL) and DOX (10 μM) in different processing conditions. (k) The particle count analysis and (l) average size of the formulated U87-AEVs using ultrasonication (one-way ANOVA with a normal distribution). All bar graphs plot data as means \pm SD of 4 independent experiments.

cells (isolated from healthy donors) compared to U87-NEVs. After incubating IL-2-stimulated PBLs with formulated AEVs and NEVs (10 $\mu\text{g/mL}$) for 72 h (Figure 6a), both vesicle types were internalized (Figure 6b). The analysis of the expression of activatory and inhibitory receptors, as well as co-stimulatory molecules, was determined on a CD3-/CD56+ gated NK cell population by multiparameter flow cytometry (Figure 6c; Note S4). While both U87-derived vesicle types—AEVs and NEVs—modulated the expression density of some NK cell receptors on IL-2-activated NK cells, U87-AEVs induced a more pronounced downregulation of the activating NK cell receptors Nkp30, NKG2D, and Nkp46, indicating stronger immunosuppressive signaling compared to NEVs. The immunomodulatory effects of AEVs on primary human NK cells were compared to NEVs derived from U87 cells.

Interactions with EVs largely influence NK cell activation and cytotoxicity, particularly those derived from tumors expressing tumor-associated antigens. These interactions involve various NK cell receptors, including activating receptors (e.g., NKG2D), co-activatory molecules, natural cytotoxicity receptors, and killer immunoglobulin-like receptors (KIRs), which can be activating or inhibitory depending on the length of their cytoplasmic tail. Additionally, inhibitory members of the NKG2 family and death receptors play a role in regulating NK cell activity. NK cells also express immune checkpoint molecules, which may impair their immunosurveillance [37, 38]. Consistent with the immunosuppressive effects observed in U87-derived AEVs, the freshly formulated Raji-AEVs, as cell-type-specific responses, also triggered a modulation of IL2-activated NK cells, reducing




FIGURE 5 | (a) Representative analysis of expression of CD9, CD63, and CD81 on the original U87 cells, secreted-/isolated NEVs, and formulated AEVs. (b) Representative Western blots of the original U87 cells (whole cell lysate: WCL) and the formulated AEVs for detecting the negative and positive exosome markers. (c) The representative analysis of the expression of cell-membrane proteins on the original Raji cell and formulated Raji-AEVs. (d) Representative immunoblots of the original Raji cells (whole cell lysate: WCL) and the formulated AEVs for detecting negative and positive exosome markers. See the whole WB membranes in Note S5. (e) The representative cryo-EM micrographs of the formulated EVs (U87) determine their morphological characteristics and protein densities. The zoom-in areas in the representative cryo-EM image are indicated by squares and marked with (*) and (**). The protein densities on the outer and luminal membrane sides of the EV's surface are shown by red arrows. The scale bars show 100 nm. The stability of U87-AEVs over 42 days, continuously kept at 5°C, is shown by (f) AEV count per mL, (g) average size (peak), and (h) representative size distribution. All bar graphs represent means ± SD from 6 independent experiments.

the expression of some stimulatory receptors, likely due to the overexpression or absence of NK ligands on the surface of the Raji cell membrane (Figure 6d). The incubation of Raji-AEVs with primary IL2-NK cells induced consistent reductions in the expression of NK receptors when compared to untreated IL2-NK cells.

Nearly all stimulatory receptors were downregulated (NKG2D, NKp30, NKp44, and NKp46), indicating that Raji-AEVs, similar to U87-AEVs, can suppress NK cell activation, consistent with the NK-resistant phenotype of Raji cells. Despite the dynamic formation of protein coronas in different microenvironments, the




FIGURE 6 | (a) The representative schematic of the immunomodulation of primary NK cells (PI-gated CD3-negative and CD56-positive of the isolated human PBLs) by incubating with the AEVs and NEVs (derived from U87 and Raji cells). (b) The representative micrograph of the PBLs incubated with the PKH-stained AEVs and NEVs (FITC-label) for 24 h at 37°C. The scale bar presents 20 μm . The MFI fold change of activating and inhibitory NK cell receptors was analyzed following IL-2 stimulation and incubation with (c) U87-AEVs and -NEVs, as well as (d) Raji-AEVs. The expression of cell surface receptors on the gated NK cell population was assessed after 72 h incubation at 37°C with IL2-NK cells (IL-2, 100 IU/mL) with or without EVs (10 $\mu\text{g}/\text{mL}$). Receptor expression fold change (relative to IL2-NK cells without EV treatment) was determined via multiparameter flow cytometry using fluorochrome-conjugated mAbs directed against activating and inhibitory receptors. Cell counts of viable cells were obtained after incubating PBLs (3×10^5 cells/well, 96-well plate) with or without treatment. Statistical analysis was conducted using one-way ANOVA with Tukey correction (normal distribution) or standard two-tailed *t*-tests (normal distribution). $n \geq 3$ donors, mean \pm SD. The gating strategy is illustrated in Figure S26. Representative images of the expression of these different receptors are presented in Figures S27 and S28.




FIGURE 7 | (a) Immunoblot of U87 cells and U87-EVs for detecting the expression of TGF- β 1 (Note S5). The ELISA study determines the release of (b) Perforin and (c) GrB from the IL-2-stimulated PBLs treated with U87-AEVs and -NEVs compared to the untreated IL-2-stimulated human PBLs. The study of $n \geq 3$ independent donors, mean \pm SD, one-way ANOVA with the Tukey correction, with a normal distribution. (d) The representative schematic of the immunomodulation of primary NK cells (PI-gated CD3-negative and CD56-positive of the isolated human PBLs) by incubating with the U87-AEVs and NEVs. The representative analysis of (e) typical ligands of NK cells expressed on the target U87 cells. (f) The annexin V-PI assay evaluates the performance of EV-treated NK cells (IL2-NK) against the target U87 cells (E:T ratio 1:1, incubation 8 h), assessing the viability of the target cells by gating CD45-negative cells ($n \geq 3$ independent donors, mean \pm SD, one-way ANOVA with the Tukey correction with a normal distribution).

AEVs with a protein corona formation likely interact with NK cells (in a medium with 10% FCS) through their native membrane proteins, facilitated by functional recognition and signaling. However, this may vary according to the microenvironment (forming different corona compositions on the surface of AEVs) and its impact on targeting and immune interactions [39].

Suppressing NKG2D, which recognizes stress-induced ligands, is commonly observed in tumor-derived NEV-treated immune cells. In addition, the internalization of U87-AEVs might also be involved in delivering immunosuppressive molecules, e.g., TGF- β 1 (Figure 7a), possibly inhibiting NK cell metabolic activity and regulating NKG2D and NKp30 through receptor endocytosis-/degradation and mTOR inhibition [40–43]. However, no changes in Perforin or Granzyme B (GrB) release (Figure 7b,c) were detected, likely suggesting complex lytic and receptor-mediated mechanisms [44–46]. Accordingly, further studies on NK cell killing capacity (Figure 7d) were performed using vesicle pre-treated IL-2 stimulated (IL2) and unstimulated (unsti)-NK cells after incubation with U87 cells as target cells (E:T, 1:1) with expressing inhibitory and stimulatory ligands (Figure 7e). Based on the Annexin V/PI assay, the killing of U87 cells after pre-treatment of IL-2-activated NK cells with AEVs and NEVs, showed a decrease in late apoptosis of the target cells with AEVs (Figure 7f). The modest immunosuppressive effect of AEVs and NEVs on unsti-NK cells remained unaffected (Figures S29 and S30). Upon stimulation, IL2-NK cells kill cancer cells via receptors like NKG2D, NKp30, NKp46, and NKG2C, using granule exocytosis, TNF family death ligands, IFN- γ , and Ab-dependent cytotoxicity [47]. However, NK cell responses depend

on a balance of inhibitory and stimulatory signals. The overall trend suggests that IL2-stimulated NK cells treated with AEVs or NEVs were slightly less effective in killing tumor targets [48]. Importantly, neither NEVs nor AEVs elicited detectable changes in activation markers on primary T cells (Figure S31). Despite the weak immunosuppressive effects on IL-2-activated NK cells against U87 cells, the similarity between the responses of NK cells to AEVs and NEVs reinforces the concept that AEVs behave as bio-interactive soft materials capable of modulating immune interfaces without triggering systemic activation, as a distinguishing feature of functional soft materials.

The mechanically formulated AEVs, which mimic NEV functions, show potential for delivering therapeutic drugs to tumor cells, thereby opening up new translational applications in cancer therapy. Unlike lipid nanoparticles, EVs possess natural homotypic affinity and require no added targeting moieties, enabling selective delivery to tumor cells while sparing healthy tissues [49]. For example, binding studies with PKH-stained U87-AEVs demonstrated a strong interaction with U87 cells compared to Raji cells (Figure 8a,b), indicating “self-recognition” via membrane markers [50, 51]. Boyden chamber assays (Figure 8c) confirmed AEVs’ ability to cross the HUVEC monolayer to reach U87 cells, suggesting the potential to traverse the tumor blood-brain barrier (a simplified Boyden chamber assay without pericytes and astrocytes). Although AEVs did not deeply penetrate U87 spheroids due to their limited vascularity, they infiltrated multiple tumor cell layers (Figure 8d), indicating a translocating capacity that could be improved with surface modifications of the AEVs.




FIGURE 8 | (a) Representative analysis and expression of positive PKH67 staining of the formulated AEVs. (b) Representative homologous targeted binding and uptake of the formulated U87-AEVs into the original U87 cells and non-specific binding toward Raji cells. The U87-AEVs, incubated with U87 (target) and Raji (control) cells, exhibit the highest interaction with the original cells, equipped with self-identifying markers, facilitating the precise identification of these cells. (c) The representative confocal images indicate the translocation of the formulated U87-AEVs (PKH67 shown in green) and their internalization into U87 cells (red), highlighting their ability to cross endothelial barriers, including those associated with the tumor blood-brain barrier. (d) A representative confocal micrograph shows the diffusion assay of the formulated PKH-AEVs into the dense U87 spheroids. Although the penetration into the spheroid core was limited due to low vascularity, the results suggest potential for deeper tissue access with surface modifications. (e) The endocytosis analysis of the formulated U87-AEVs (PKH staining, shown in green) was performed using a pharmacological inhibition assay, which revealed primary uptake via clathrin- and macropinocytosis-mediated endocytosis, with a lesser contribution from caveolae and pinocytosis. (f) The intercellular trafficking of internalized U87-AEVs (green color) into intracellular compartments of U87 cells is demonstrated by representative confocal fluorescence micrographs of endosomes, mitochondria, and other organelles, attributed to their moderate negative surface charge. Pearson's correlation coefficient is shown in Figure S32. The analyzed expression of (g) the common vesicle's tetraspanins on the formulated DOX-AEVs with and without implementing acoustics (Figure S33), and (h) the proliferation rate of U87 cells incubated (72 h, 37°C) with the formulated DOX-AEVs (20 μg/mL) (n = 5 independent samples, mean ± SD). The functionality of the therapeutic cargo and the biological integrity of AEVs are shown by the delivery of (i) GFP mRNA and (j) GFP Cas9 and their expression (see more micrographs and analyses in Figures S34 and S35).

Mechanistic uptake studies showed that AEV internalization is primarily mediated by clathrin- and macropinocytosis-dependent pathways, with lesser involvement from caveolae and pinocytosis (Figure 8e) [52]. Internalized AEVs trafficked mainly to endosomes and mitochondria (Figure 8f), likely influenced by their moderate negative charge [53]. As a measure of therapeutic efficacy, once internalized into U87 cells, e.g., DOX-AEVs, whether formulated with or without acoustic thermal phenomena (Figure 8g), their proliferative capacity was reduced after 48 h (Figure 8h), confirming stable drug encapsulation and preserved functionality. Taking advantage of potential endosomal escape, beyond mitochondrial localization, μ -chip-formulated AEVs successfully delivered functional GFP mRNA to the cytosol (Figure 8i) and enabled nuclear delivery of GFP-tagged Cas9 (Figure 8j). Formulated AEVs, programmable soft materials with preserved surface architecture produced by point-of-need microfluidics, provide a standardized pathway for future exploration in biomedicine and beyond.

3 | Conclusion

A multiphysics-driven microfluidic platform is introduced to transform AEV production from an empirical, trial-and-error process into a predictable materials design framework. By integrating nanoknife-assisted rupture, herringbone-mediated chaotic mixing, and acoustothermal modulation into a single, flow-optimized device, a quantitative structure-process-function design that values multiphysics and biological perspectives is developed for vesicle formation, preservation of biomimetic functionality, and therapeutic encapsulation. The high-yield and reproducible assembly of formulated biomimetic AEVs ($\geq 5 \times 10^9$ vesicles per million cells and ≥ 2 -fold higher than conventional configurations without HB configurations) was achieved in this tunable platform, preserving narrow size distributions (< 150 nm) and stable membrane proteins. The performed analytical and biological assays show the high-affinity interactions and effective homotypic uptake of the formulated AEVs, as well as their ability to cross endothelial barriers for therapeutic delivery and to modulate NK cell receptor expression, similar to tumor-derived vesicles. Taken together, the optimized geometric configurations obtained from controlled Multiphysics can be designed to be compatible with low-cost fabrication materials, allowing for use with standard benchtop equipment in point-of-need settings with high reproducibility of the biomimetic vesicle formation process, developing next-generation programmable biomaterials.

4 | Methods

4.1 | COMSOL Multiphysics Simulation of Integrated μ -Chips

Before the experimental analysis, 3D physics simulations were performed using COMSOL Multiphysics 6.2 (COMSOL AB, Stockholm, Sweden) to understand and optimize particle flow behavior (Note S1). The simulations were constructed in a 3D geometry using a rectangular prism with an overall channel height of $50 \mu\text{m}$ and variable widths. A $350 \mu\text{m}$ channel length was used to ensure that six herringbones could fit within the channel length across all tested parameters. An asymmetric boundary

condition was used in the middle of the herringbones to reduce the computational cost, except for the staggered herringbone designs, where this symmetry no longer exists. Water was used as the fluid for the Laminar Flow study (Schiller-Naumann Drag Correlation), with a density of 1000 kg/m^3 and a dynamic viscosity of $0.001 \text{ Pa}\cdot\text{s}$, with each simulation using a volumetric flow rate of $2 \mu\text{L/s}$ ($2 \times 10^{-9} \text{ m}^3/\text{s}$) applied at the inlet. Cell paths were modeled using the Particle Tracing Module within COMSOL, where the cells were represented as particles with a diameter of $10 \mu\text{m}$ and a density of 1050 kg/m^3 . To assess cell interaction with the knife, a Wall Distance module within COMSOL was used, where a collision was defined as occurring when the cell's radius was less than its distance. When this condition was met, the particle would freeze in place and remain stationary in the position where it collided with the knife. The force plots were assessed by changing this condition to a "Bounce," where the cell's velocity would be reflected from the surface of the knife, so it could continue through the simulation to assess the forces experienced by the cell throughout the channel. The particle force data were obtained from the 50 independent particles dispersed at random positions at the inlet of the geometry.

For acoustothermal simulations, the methodology encompasses laminar flow analysis, pressure acoustic frequency domain studies, particle tracing, and heat transfer evaluations to establish optimal conditions. Simulations were performed using glycerol, incorporating materials such as silicon nitride and PDMS channels. Acoustic pressure was varied around 1 MPa (Note S3), and the frequency domain was set to 9.73 MHz (based on the actual frequency of the piezo transducer) to determine heat transfer and optimal particle trapping conditions (at different flow rates and channel dimensions). The acoustophoretic radiation, drag, and lift forces were studied to evaluate particle behavior in time-dependent simulations. The studied heat transfer considered the lowest working temperature by keeping it under 50°C (a short thermal impact), including the convective heat flux and surface radiation effects (with the defined boundary conditions, no-slip walls for fluid flow, static outlet conditions, sound-hard boundary walls for acoustic reflection, and impedance-matched fluid interfaces). The assumptions were also considered (i) fully developed laminar flow ($2 \mu\text{L/s}$), (ii) ideal material properties for silicon nitride and PDMS (perfectly matched layers), and (iii) negligible external thermal influences. For the acoustothermal heat simulation, it was also assumed that (1) the air boundary had a constant temperature of 278.15K and that (2) water was flowing from the inlet. The initial temperature of all domains was chosen to be 278.15K . In this simulation, heat due to radiation was neglected. The non-isothermal flow multiphysics interfaces solve for the conservation of energy, mass, and momentum in fluids, as well as the conservation of energy in solids. This is bidirectional coupling, which helps to solve the temperature in the water more precisely. The other boundary conditions and parameters already mentioned above have been included in the heat transfer simulations for the heater-integrated μ -chips.

4.2 | Fabrication of Nanoknife Arrays

Before the fabrication, the nanoknife structures were designed using AutoCAD (Autodesk, San Francisco, CA, U.S.) and KLayout

software (Table S1). Accordingly, a silicon wafer ($300 \pm 15 \mu\text{m}$ silicon wafer with double side $100 \text{ nm} \pm 0.5\%$ passivation Si_3N_4 , orientation $100 \pm 0.5^\circ$, type p, SIEGERT WAFER GmbH, Aachen, Germany) was first cleaned with isopropanol and water, heated at 110°C for 5 min and coated with a primer (TI prime, MicroChemicals GmbH, Ulm, Germany) to enhance adhesion of the photoresist before spin coating (4000 rpm for 30 s, soft bake at 120°C for 120 s). The photoresist AZ 5214E (MicroChemicals) was then coated onto the silicon wafer at 4000 rpm for 30 s, followed by a soft bake step at 110°C for 60 s. Next, the wafer was exposed with a laser writer (MLA 100, Heidelberg Instruments) at 60 mJ/cm . After exposure, the wafer was developed using the developer solution AZ 726 MIF (MicroChemicals) for 60 s and washed with water. Next, the Si_3N_4 wafer was etched using plasma physical etching (Etchlab 200, SENTECH Instruments GmbH, Berlin, Germany) under the following conditions (pressure 5 Pa, flow 30 sccm, power 250 W, and time 120 s). After that, the wafer was sawn into $2 \text{ cm} \times 5 \text{ cm}$ pieces using a Wafer Saw SS10 (Accretech, München, Germany). To avoid the break, a photoresist was put on the wafer to protect the surface during the sawing process and then removed. Next, the silicon wafer was chemically etched using potassium hydroxide (KOH, 40% w/v, Bernd Kraft GmbH, Haag, Netherlands) at 80°C (Arias Wet benches PLM 717-1, Schwerte, Germany) for 55 min, thereby undercutting the Si_3N_4 to create nanoknives. Afterward, the photoresist AZ 5214E was removed and rested in the water overnight.

4.3 | Fabrication of HB-Patterned PDMS Channels

Using COMSOL simulation to guide the optimization of geometric parameters, herringbone upper constraint structures made of PDMS were fabricated using SU-8 molds. The herringbone channels, designed using the optimized parameters, were then created in AutoCAD with a length of 2 cm, a height of $50 \mu\text{m}$, and a width of $100 \mu\text{m}$, featuring an inlet and outlet. To create the herringbone upper constraint structures, a two-layer photolithography process (Table S2) was done on a silicon wafer ($381 \mu\text{m} \pm 25 \mu\text{m}$ CZ-Si wafer with single side polish, type p, 1–20 $\Omega \text{ cm}$), washed with acetone and isopropanol using an ultrasonic cleaner, and dried with nitrogen gas to ensure a clean surface. The silicon surface was activated using oxygen plasma and subsequently pre-baked at 120°C for 5 min to enhance the adhesion between the wafer and photoresist. For the first photolithography layer, the permanent epoxy negative photoresist SU-8 3010 (MicroChemicals) was spin-coated on the wafer to achieve a height of $15 \mu\text{m}$ (500 rpm for 10 s and 1000 rpm for 30 s) using a spin coater (Model WS-650MZ-23NPPB 0, Laurell Technologies Corporation, Lansdale, PA, U.S.). The coated wafer was baked at 95°C for 10 min on a hot plate to reduce the solvent concentration in the resist film and improve adhesion and stability.

A maskless lithography approach was then employed using a 2D laser writer (Dilase 250, Kloe, Saint-Mathieu-de-Trévières, France). The design structures were created in the KloeDesign software (spot size: $1 \mu\text{m}$, overlap rate: 50%). The writing velocities were set to 10 mm/s for fill, 0.5 mm/s for contour, and 20% modulation. After laser writing, the wafer underwent a post-exposure bake (95°C for 4 min). Once the first layer was ready, it was coated with a second layer of epoxy-negative photoresist SU-8

3025 (MicroChemicals) using a spin coater to achieve a height of $35 \mu\text{m}$ (500 rpm for 10 s and 2000 rpm for 30 s). The coated wafer is soft-baked on a hot plate at 95°C for 11.5 min. Then, a maskless lithography approach was employed using the 2D laser writer. Using the angular compensation feature, the upper constraint herringbone design was first aligned in the KloeDilase software and printed by the writing velocity of 15 mm/s (filling), 5 mm/s (contouring), 1 mm/s (trajectories), and the modulation of 30% (spot-size $1 \mu\text{m}$, overlap rate 50%, filter focus 0.06 mm). After the second laser writing, the wafer underwent a post-exposure bake (95°C , 5 min). Once baked, the structures were developed by dissolving the non-exposed photoresist (7 min in MR-Dev 600, Micro Resist Technology GmbH, Berlin, Germany). Finally, the wafer was washed with acetone and isopropanol, dried with nitrogen, and stored in a petri dish with the lid facing upward. For the standard channel without the HB patterns, a single-layer, coated SU8 with a height of $50 \mu\text{m}$ was used to print the channel, including the inlet and outlet, using the laser writer's parameters mentioned earlier.

For preparing PDMS channels (with and without HB patterns), the curing agent and PDMS (Sylgard184 Silicone Elastomer Base, Dow Chemical, Midland, MI, U.S.) were mixed in a 1:10 ratio using a plastic spoon in a plastic cup until bubbles formed. Next, the mixture was poured into the petri dish on the wafer with the structures, and the bubbles were removed using a desiccator. The PDMS was cured by baking in an oven at 65°C for 60 min. After baking, the cured PDMS with the microfluidic channels (with and without HB patterns) was cut using a razor blade, and the holes for the inlet and outlet were punched with a biopsy puncher (size $500 \mu\text{m}$). To bond the herringbone PDMS channels to the silicon wafer containing the nanoknife structures, air plasma treatment was performed using a Zepto Model 8 Type B Diener device (air pressure: 0.8 mbar, time: 60 s, and power: 30 W). Before the air plasma treatment, the chips and the PDMS channel were washed with isopropanol and dried with nitrogen to ensure a clean surface. Immediately after plasma surface activation, the PDMS channels were aligned on the knife array using a stereo microscope (SMZ800, Tokyo, Japan), and they were left overnight in an oven at 120°C to ensure a strong and stable bond.

4.4 | Cell Culture

The human glioblastoma U87 cell line (ATCC, Manassas, VA, U.S.)—as well as a stable GFP-expressing U87 cell line [54] (Note S2.4) used as a control—were cultured in supplemented Dulbecco's Modified Eagle Medium (DMEM, Sigma-Aldrich, Burlington, MA, U.S.) with glucose (4 g/L glucose, Sigma-Aldrich). The human lymphoblast-like Raji cell line (ATCC CCL-86) was cultured in the supplemented Iscove's Modified Dulbecco's Medium (IMDM, Sigma-Aldrich). The isolated PBL cells were primarily cultured in RPMI-1640 medium supplemented with additional components. All media used were supplemented with 10% v/v heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich), 1% v/v antibiotics (100 IU/mL penicillin and 100 $\mu\text{g}/\text{mL}$ streptomycin; Sigma-Aldrich), and 2 mM L-glutamine (Sigma-Aldrich). The cultured cells were incubated at 37°C with 5% CO_2 and 95% humidity, and their viability was assessed before each experiment using the trypan blue exclusion assay.

4.5 | Formation of AEVs in μ -Chips

U87 cells cultured in T75 cell culture flasks (Greiner BIO-ONE, Kremsmünster, Austria) reached the confluency of 70% and were washed thoroughly using BPS (twice) to discard the cell medium containing debris and secreted NEVs. The cells were then trypsinized using TrypLE Express (Thermo Fisher Scientific Inc., Waltham, MA, U.S.) and resuspended in PBS ($\sim 2 \times 10^6$ cells/mL of cells) were collected and centrifuged at $500 \times g$ for 5 min at 5°C (Thermo Scientific Megafuge 16R Centrifuge). The supernatant was discarded, and the cell pellet was washed twice with PBS (centrifuged at $500 \times g$ for 5 min at 5°C). The cell pellet was then resuspended in 2 mL of freshly prepared PBS solution for running through the μ -chips.

The μ -chips were mounted on a peristaltic pump (Ismatec IPC Pump, Dachau, Germany) to prepare the setup for producing AEVs. PTFE-chemical tubes (Standard type: RCT-ZS-DKA-SW, Inner- \varnothing : 0.3 mm, Outer- \varnothing : 0.8 mm) were used to connect the channel inlet and outlet with the sample container. The prepared cell sample (2 mL) was then run for 60 min, considering a flow rate of $2 \mu\text{L/s}$. The samples were gently pipetted at 5-min intervals to ensure the cells did not settle down (stay floating). After the run, the samples were well mixed using pipettes, and the cells were counted to check the number of cells remaining after the rupturing procedure. The recovery process was performed in accordance with established protocols [55, 56].

Note, for forming AEVs from RBCs, the isolated and cleaned RBCs, devoid of platelets and other blood cells, were washed and resuspended in PBS at a concentration of 7 million cells/mL, following the same procedure as for the cancer cells.

In the first method (ultrafiltration), the samples in Eppendorf Safe-Lock Tubes were centrifuged at $800 \times g$ for 5 min at 5°C (Thermo Scientific Fresco 21 Centrifuge) to remove any remaining live and dead cells. The collected supernatant was centrifuged again at $2000 \times g$ for 10 min at 5°C to remove partially ruptured cells, large debris, and aggregates from the collected samples. Next, the collected supernatant was filtered through a centrifugal filter (Millipore Ultrafree CL Centrifugal Devices—hydrophilic PTFE membrane, $0.45 \mu\text{m}$, Sigma-Aldrich) at $500 \times g$ for 5 min at 5°C , ensuring the removal of large intracellular compartments and debris. The sample was filtered and washed using a centrifugal filter (Millipore Amicon Ultra-2 mL Centrifugal Filters Ultracel 100 K) at $2500 \times g$ for 5 min at 5°C to collect the formed AEVs.

In the second approach (ultracentrifuge gradient density) [14, 19], the samples containing the produced AEVs and cell debris, after centrifugation at $500 \times g$ (15 min at 5°C), were placed on the top part of a density gradient OptiPerp (30 and 10% v/v) and then centrifuged at $100\,000 \times g$ for 60 min at 5°C , collecting the formed AEVs settled at the top of the 30% density gradient.

After recovery, the formulated AEVs were analyzed by Particle-Metrix (1:1000 or 1:100 dilution in filtered DPBS, Particle-Metrix GmbH, Ammersee, Germany) and Malvern zeta sizer (Malvern Panalytical Ltd, Malvern, UK). The protein content was obtained using Pierce BCA and Qubit Protein Assay Kit (Thermo Fisher

Scientific Inc.). The formulated GFP-AEVs, derived from GFP-expressing U87 cells (Ex. 495 nm and Em. 515 nm), were analyzed using a fluorometer (BMG LABTECH, Ortenberg, Germany) at a constant gain for all measurements.

After the AEV formation, a washing procedure was performed to clean the μ -chip devices and tubing with a flow cytometry cleaning solution (BD FACSClean Solution, Franklin Lakes, NJ, U.S.) for 10 min (flow rate $2 \mu\text{L/s}$), DI water (10 min, $2 \mu\text{L/s}$), and PBS (20 min, $2 \mu\text{L/s}$), preparing the device for other runs and other cell types.

4.6 | Isolation of NEVs

An ultracentrifugation approach will isolate NEVs from U87 cells (1×10^7 cells/mL) [55, 56]. Briefly, to isolate NEVs, U87 cells were washed and incubated in an exosome-free FCS medium for 24 h in advance. Next, the medium was centrifuged at $500 \times g$ (5 min) and $10\,000 \times g$ (20 min) to remove small debris and concentrate using centrifugal filter units (100 kDa, $3000 \times g$, 15 min). The medium was then centrifuged ($100\,000 \times g$, 120 min) to collect NEVs, and the NEVs were washed with PBS to purify them through another centrifugation step ($100\,000 \times g$, 120 min). The protein content was determined using the Pierce BCA and Qubit Protein Assay Kit (Thermo Fisher Scientific Inc.).

4.7 | In Channel Cell Damage Analysis

To evaluate cell damage during the AEV-formation process using μ -chips, PI ($1 \mu\text{g/mL}$) was added to the reservoir of the floating cells (2 million cells/mL, 2 mL) and circulated for 20 min at 5°C . Afterward, the sample that had passed through the μ -chips was collected and centrifuged ($500 \times g$, 5 min). To roughly estimate the interaction rate, the pallet was analyzed by flow cytometry to detect the internalization of PI (PI-positive cells) into the damaged/ruptured cells.

4.8 | Acoustothermal-Based DOX Encapsulation Process

To fabricate DOX-AEVs (AEVs loaded with DOX) using the acoustic-assisted method, cell suspension (1 million/mL) was transferred to a 2 mL Eppendorf tube connected to the inlet/outlet of μ -chips (mounted on a peristaltic pump with $2 \mu\text{L/s}$) were placed on top of a ceramic-coated piezoelectric transducer (production number 405926, ceramic type: Pz26, and peak frequencies of 1.73, 5.7, and 9.7 MHz, Meggitt PLC, Coventry, UK). The optimal resonance frequency and the voltage input were set at 9.7 MHz and 60 Vpp, respectively. The sample underwent closed-cycle runs for 60 min, with glycerol serving as a thermal and vibrational coupling medium between the silicon nitride chip and the piezoelectric device. The cell suspension was maintained in an ice-cold environment (5°C). Samples were pipetted every 5 min to prevent potential cell sediment. All setups (e.g., silicon nitride chip, piezoelectric device, and pump) were kept in a cold room fridge to prevent temperature rise. After purification, the formulated DOX-AEVs (Ex. 495 nm and Em. 585 nm) were analyzed by a fluorometer at a constant gain for all

measurements and Particle-Matrix (1:1000 dilution in filtered DPBS). The proof-of-concept experiments for cargo loading (DOX, GFP mRNA (Miltenyi Biotec, Bergisch Gladbach, Germany), and GFP Cas9 protein (CAS9GFPPRO, Sigma-Aldrich)) were performed as described above using the designed μ -chips with and without the acoustothermal-based process.

4.9 | Thermal-Based DOX Encapsulation Process

To fabricate DOX-AEVs using the thermal-assisted method (control study for acoustic-assisted approach), a cell suspension (1 million/mL) was transferred to a 2 mL tube connected to the inlet and outlet of μ -chips mounted on a peristaltic pump operating at a flow rate of 2 μ L/s. The μ -chip was then placed on a heater with controlled temperature. The sample was run in a closed-cycle for 60 min, with glycerol placed between the silicon nitride chip and the heater. The cell suspension was kept at an ice-cold temperature (5°C), and pipetted every 5 min to prevent cell sedimentation. All experiments and setups were conducted in a refrigerated environment. After purification and removing free DOX, the formulated DOX-AEVs (Ex. 495 nm and Em. 585 nm) were analyzed by a fluorometer.

4.10 | Ultrasonication-Based DOX Encapsulation Process

To fabricate DOX-AEVs using ultrasonication (control study for the acoustic-assisted approach), a cell suspension (1 million cells/mL) was transferred to a 2 mL tube. The ultrasonicator (30 kHz frequency, total duration of 5 min; 0.5 s of sonication and 0.5 s pause, 100% amplitude, performed in an ice box at 5°C) [31] was then placed into the tube with the cells (with and without DOX). The cell suspension was maintained at an ice-cold temperature (5°C) during the procedure. All experiments and setups were conducted in a refrigerated environment. After following the earlier-mentioned purification and removing free DOX, the formulated DOX-AEVs (Ex. 495 nm and Em. 585 nm) were analyzed by a fluorometer.

4.11 | Flow Cytometry of U87 and Raji Cells

Cells (250×10^5) were trypsinized and washed twice with ice-cold flow cytometry buffer, consisting of phosphate-buffered saline (PBS; Life Technologies) supplemented with 10% (v/v) fetal bovine serum (FBS; Sigma-Aldrich). The cells were then incubated with FITC-labeled mAbs targeting CD9, CD63, CD81, and CD19, as recommended by the manufacturers, for 30 min on ice in the dark. Following incubation, the cells were washed with flow cytometry buffer and centrifuged ($500 \times g$, 5 min). After an additional wash step, PI (1 μ g/mL, Sigma-Aldrich) or SYTOX Blue Dead Cell Stain (1 μ M, Thermo Fisher Scientific Inc.) was added immediately before flow cytometry to exclude non-viable cells. The expression of membrane receptors or intracellular proteins was assessed using a MACSQuant Analyzer 9 flow cytometer (Miltenyi Biotec), and the data were analyzed with FlowJo software (version 10.10, Ashland, OR, U.S.). FITC-labeled mouse IgG1 isotype control was used to evaluate nonspecific binding. Positivity for each marker was determined by subtracting

the percentage of cells stained with the isotype control from the percentage of cells positively stained with the specific mAbs.

4.12 | Western Blot Analysis

Cell pellets were lysed using RIPA buffer supplemented with protease inhibitor tablets (cOmplete, Roche Diagnostic GmbH, Vienna, Austria) and phosphatase inhibitors (PhosphoSTOP, Roche Diagnostic GmbH). For AEVs, homogenization was performed with reducing reagents alone. Protein concentration was measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc.). Proteins per sample of the prepared AEVs and whole cell lysate (WCL) were resolved by SDS-PAGE (8%–15% w/v) and transferred to activated polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 1 \times Roti block buffer for 60 min at RT and incubated overnight at 4°C with primary mAbs diluted in the same buffer (CD9, TSG101, mHsp70, GPR94, Calnexin, Actin, and GAPDH). Following primary mAb incubation, membranes were treated with the appropriate secondary Abs (rabbit, goat anti-mouse) in the Roti block buffer (1 \times) for 60 min at RT. Protein bands were detected using the Pierce ECL Western Kit (Thermo Fisher Scientific Inc.) and imaged with the ChemiDoc Touch Imaging System (Bio-Rad, Hercules, CA, U.S.).

4.13 | Cryo-EM Imaging Assay

The AEV sample (3 μ L of $\sim 2.5 \times 10^8$ EVs/ μ L) was applied on an oxygen-plasma cleaned (Gatan Solarus 950, Pleasanton, CA, U.S.) Quantifoil 2/1 holey carbon grid, Cu 200 mesh (Quantifoil Micro Tools, Großlobichau, Germany), and plunge-frozen into an ethane/propane 1:1 mixture using the Leica EM GP2 (100% humidity, blot time 6 s, 20°C). Grids were loaded into a Titan Krios G4 transmission electron microscope operated at 300 kV, equipped with a CFEG electron source, a Falcon4i direct detector camera, and a Selectris X energy filter (Thermo Fisher Scientific Inc.). Images were collected in electron-event representation (EER) using Smart EPU (Thermo Fisher Scientific Inc.) [57, 58]. All datasets were collected at a magnification of $\times 53\,000$, resulting in a pixel size of 2.212 Å, with acquisition times ranging from 5 to 6 s and a total dose of 40 $e^-/\text{Å}^2$. A total of 5694 movies were imported into cryoSPARC v.4.6.1 and subjected to patch motion correction [59]. The resulting thumbnails were visually sorted for “AEV containing” micrographs (358), and their patch contrast transfer function was estimated. Finally, a curated set, e.g., of 88 full-frame visible AEVs was screened. For the figure presentation, some representative micrographs were low-pass filtered to a resolution of 10 Å and exported as PNG.

4.14 | MTT Proliferation Assay

According to the manufacturer’s protocol (MTT assay, Thermo Fisher Scientific Inc.), the proliferation rate of U87 cells (5000 cells per well, 96-well plate) was evaluated after adding different formulated DOX-AEVs (20 μ g/mL) compared to U87 cells that were either untreated or incubated with empty AEVs (Incubation for 72 h at 37°C). After incubating with MTT reagent ((3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazoliumbromid),

5 mg/mL, 4 h) and dissolving the produced formazan in dimethyl sulfoxide (DMSO, 50 μ L), the absorbance was measured at a specified wavelength of 570 nm using a microplate reader.

4.15 | PKH-Stained NEVs

To obtain FITC-labeled NEVs, the formed NEVs were stained using a PKH67 green fluorescent cell linker kit (Sigma–Aldrich) according to the manufacturer’s protocol. Briefly, the plate containing the formed NEVs was mixed with 1 mL of Diluent C and sonicated for 5 min. Next, PKH67 dye (5 μ L) was added to the NEVs/Diluent C mixture, mixed for 30 s by gentle pipetting, and incubated for 5 min at RT. The PKH67 dye in the mixture was quenched by adding 2 mL of 10% w/v bovine serum albumin (BSA) in PBS, followed by the slow addition of 1.5 mL of the 0.971 M sucrose solution to the bottom of the centrifuge tube, which kept the exosome-dye solution on top. The mixture was centrifuged at 100 000 \times g for 120 min at 5°C. Next, the stained pellet was resuspended in PBS by gentle pipetting and transferred to an Amicon 10 kDa MWCO filter column (3000 \times g, 20 min) to remove free dyes. Afterward, the samples were analyzed by flow cytometry. The FITC-NEVs were prepared and used fresh for all experiments.

4.16 | PKH-Stained AEVs

The PKH67-stained U87 cells, obtained following the manufacturer’s protocol (PKH67 green fluorescent cell linker kit, Sigma–Aldrich), were washed twice with complete medium and PBS. Afterward, the suspended PKH67-stained U87 cells were added to the μ -chips to form FITC-stained AEVs in the knife array channel described above (Formation of AEVs in μ -chips). To remove free dyes, the FITC-stained AEVs were washed with additional ultracentrifugation (100 000 \times g, 120 min), and the resulting pellet was diluted in PBS for further experiments.

4.17 | PBL Isolation

PBLs were isolated from the peripheral blood of healthy donors using density gradient centrifugation. The anonymous collection of PBLs from healthy volunteers and the use of PBLs complied with ethical standards approved by the Technical University of Munich Ethics Commission (Protocol code 2428/09). The isolated PBLs were cultured in a medium containing low-dose IL-2 (100 IU/mL; PeproTech, Rocky Hill, NJ, U.S.) at 37°C for 72 h, following established protocols [45].

4.18 | Microscopy Studies

PBLs (5×10^4 cells) were seeded onto poly-L-lysine-coated glass slides (Sigma–Aldrich) and kept overnight. The cells were then incubated with the formed AEVs and the isolated NEVs, washed twice with PBS, and fixed in 3.6% paraformaldehyde (PFA, Sigma–Aldrich) for 15 min at RT. After washing, the fixed cells were stained with phalloidin (1 μ g/mL, 60 min) and Hoechst (2 μ g/mL, 10 min, Sigma–Aldrich) for F-actin and nuclear visualization at RT in darkness. Imaging was performed using a Leica Confocal

fluorescence microscope with a 63x oil objective, and the images were analyzed using Leica LAS X software.

4.19 | Flow Cytometry of PBLs

Analysis of CD3-negative and CD56-positive gated NK cells derived from PBLs (untreated, IL-2 (100 U/mL), IL-2/AEVs (100 U/mL + 10 μ g/mL), and IL-2/NEVs (100 U/mL + 10 μ g/mL)) was performed using fluorescence-conjugated monoclonal Abs (mAbs) detecting typical receptors (Table S3) of human primary NK cells [45]. Receptor expression on PI (1 μ g/mL)-negative viable cells, washed using flow cytometry (FACS) buffer, was quantified using a MACSQuant Analyzer 9 flow cytometer, and data analysis was done with FlowJo software (version 10.8). Percentages of positive cells and mean fluorescence intensity (MFI) values were calculated relative to isotype controls. The T cells were also gated using CD3-positive and CD56-negative cells derived from PBLs (untreated, IL-2 alone, IL-2 + AEVs, and IL-2 + NEVs) as a control population.

4.20 | GrB and Perforin ELISA Assay

The ELISA kits were used to measure GrB (DuoSet ELISA, R&D Systems, Minneapolis, MN, U.S.) and Perforin (BIOZOL Diagnostik Vertrieb GmbH, Eching, Germany) by preparing all reagents and samples according to the manufacturer’s instructions. Briefly, standards and samples were added to the wells of a pre-coated microplate, and then the plate was incubated for 120 min at RT. After washing, add the detection GrB and Perforin mAbs, then the secondary horseradish peroxidase (HRP)- conjugated Abs, and incubate again (60 min). After another series of washes, add the substrate solution (ECL Kit), which will react with the enzyme to produce a color change. The color intensity was proportional to the amount of Perforin and GrB in the samples, and the absorbance was measured at a specified wavelength, 590 nm, using a microplate reader.

4.21 | Expression Level of Cancer Cell Receptors

Analyzing by flow cytometry, e.g., U87 cells (2×10^5 cells) were incubated in a FACS buffer containing fluorescence-conjugated mAbs, including MIC-A, MIC-B, HLA-DR, HLA-E, ULPBs, CD47, and HLA-ABC as well as isotype controls (mouse IgG1, BD Biosciences, San Jose, CA, U.S.) for 30 min on ice in the dark. The cells were washed, resuspended in a FACS buffer containing PI (1 μ g/mL), and analyzed using FlowJo software.

4.22 | Annexin V/PI Apoptosis Assay

According to the manufacturer’s protocol, cell death was assessed using an Annexin V/PI apoptosis assay (Abcam, ab14085). U87 target cells (2×10^5 cells/well) were co-incubated (8 h, 37°C with 5% CO₂) with effector NK cells at a 1:1 ratio. After incubation, the cells were harvested and resuspended in a binding buffer containing Annexin V-FITC and PI for 5 min at RT in the dark. During flow cytometry analysis, target cells were identified and gated by excluding NK cells labeled with anti-CD45 mAb.

4.23 | Homologous Targeting Assay

In the flow cytometric analysis, FITC-stained AEVs were used to analyze internalization into target cells (U87 and Raji). These cell lines (2×10^5 cells per well) were suspended in 96-well plates, and then FITC-stained AEVs (10 $\mu\text{g}/\text{mL}$) were added and co-incubated for 60 min at 4°C. Afterward, the treated U87 and Raji cells were centrifuged (500 $\times g$, 5 min), washed twice with cold DPBS, and Analyzed Using Flow Cytometry. The PI-negative cells were gated to detect FITC-positive cells (containing the FITC-AEVs).

4.24 | Endocytosis Assay

To study the endocytosis mechanism for FITC-AEVs, the cells were pre-incubated with different inhibitors (monodansylcadaverine 150 μM , clathrin-mediated endocytosis inhibitor, filipin 5 $\mu\text{g}/\text{mL}$, and Nystatin 50 $\mu\text{g}/\text{mL}$, caveolin-mediated endocytosis inhibitor, and amiloride 25 μM and nocodazole 20 μM , macropinocytosis inhibitor) for 120 min at 37°C [60, 61]. The viability of the inhibitor-treated cells has been checked to confirm the sub-lethal dosage. The inhibitor-treated cells were washed twice and then incubated with a freshly prepared medium containing FITC-AEVs (20 $\mu\text{g}/\text{mL}$) for 120 min (37°C). Following incubation, the cells were washed with DPBS and FACS buffer. A negative control group (untreated cells) and a positive control group (cells incubated with FITC-AEVs without inhibitor treatment) were included for comparison. Endocytosis inhibition was assessed by normalizing the geometric mean fluorescence of inhibitor-treated wells to that of the control wells. The PI-negative (live) cells were gated using FlowJo software for analysis of uptake.

4.25 | Intracellular Trafficking of FITC-AEVs

U87 cells were incubated with FITC-AEVs for 24 h and then fixed with PFA (3.6% w/v). Next, organelles were stained according to the manufacturer's instructions and imaged with confocal microscopy. Briefly, lysosomes were stained with LysoTracker Red DND-99 (1 μM , 30 min, Thermo Fisher Scientific Inc.), mitochondria were stained with MitoTracker Red (1 μM , 30 min, Thermo Fisher Scientific Inc.), and endoplasmic reticulum (ER) was stained with ER-Tracker Red (1 μM , 30 min, Thermo Fisher Scientific Inc.) [62]. ImageJ performed the colocalization of AEVs in different subcellular organelles using Pearson's coefficients.

4.26 | Boyden Chamber Assay

A simplified Transwell translocation assay (without pericytes and astrocytes) for the formulated AEVs involves seeding endothelial cells (HUVEC) onto the upper chamber of a Transwell insert with a porous membrane (1 μm) and U87 cells in the bottom chamber. After allowing HUVEC cells to adhere and grow to full confluence, FITC-AEVs (20 $\mu\text{g}/\text{mL}$) are introduced into the upper chamber containing the HUVECs and incubated for 24 h. To quantify translocation and uptake, the U87 cells were then fixed, stained with phalloidin (actin) and Hoechst (nuclei) dyes, and

analyzed by confocal microscopy compared to the untreated U87 without incubation with FITC-AEVs.

4.27 | Spheroid Diffusion Analysis

U87 spheroids were prepared by seeding 3000 cells into the low-adherent 96-well plates for 48 h until forming a spheroidal structure. Next, the formulated spheroids were washed (PBS) and incubated with FITC-AEVs (20 $\mu\text{g}/\text{mL}$) for an additional 48 h. After a washing step (PBS), the spheroids were then fixed and stained with phalloidin and Hoechst dyes to perform confocal microscopy analysis.

4.28 | Statistical Analysis

Based on N independent experiments, data were reported as the mean \pm standard deviation ($\pm\text{SD}$). All experiments were conducted in triplicate at least, unless otherwise noted. Normality of the data (normal or log-normal distribution) was determined using the Shapiro-Wilk omnibus test. Statistical comparisons were conducted using the appropriate data analysis format. Two-tailed unpaired t -tests and one-way analysis of variance (ANOVA) tests, followed by Tukey's post-hoc multiple comparisons, were conducted for datasets that followed Gaussian distributions. Based on the comparison test, for non-Gaussian distributions, the two-tailed Mann-Whitney test was employed to compare two groups, and the Kruskal-Wallis test, followed by Dunn's multiple comparisons, was used to compare more than two groups. All statistical analyses were performed using GraphPad Prism version 10.

Author Contributions

Methodology: T.S., I.G., A.C., B.A., A.B.D., H.R., A.B., R.H., J.B., C.J.O.K., E.B., S.P.; Writing – original draft: T.S., I.G., A.C., M.H.K.; Supervision, Discussion, review, revision, and editing: S.D.R., K.N., G.M., and O.H.; Conceptualization, methodology, supervision, funding acquisition, discussion, review, revision, and editing: M.H.K. All authors have read and agreed to the published version of the manuscript. All authors declare no conflicts of interest.

Acknowledgements

This research was supported by Deutsche Forschungsgemeinschaft (DFG 556461968), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 899987, and TranslaTUM Seed Fund (TUM). I.G.'s research stay was supported by a Fulbright fellowship. B.A. was supported by the German Federal Ministry of Research, Technology, and Space (BMFTR) under grant 02NUK064B. The authors acknowledge the support and access to the cryo-EM infrastructure provided by the Department of Cell and Virus Structure at the Max Planck Institute of Biochemistry (Martinsried, Germany). The authors also thank Ms. Anett Lange (TUM hospital), Mr. Reiner Dunkl (TranslaTUM), Mr. Wolfgang Kurz (TranslaTUM), Mr. Moritz Leuthner (TranslaTUM), Mr. Dennis Hofmann (IFW Dresden), Ms. Cindy Kupka (IFW Dresden), Ms. Joyce Kache (TUM hospital), Dr. Anika Kwiatkowski (ZEITlab, TUM), and Dr. Markus Becherer (ZEITlab, TUM) for their assistance. Schemes are partially created with BioRender.com (Toronto, CA).

Open access funding enabled and organized by Projekt DEAL.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

References

1. L. Cheng and A. F. Hill, "Therapeutically Harnessing Extracellular Vesicles," *Nature Reviews Drug Discovery* 21, no. 5 (2022): 379–399, <https://doi.org/10.1038/s41573-022-00410-w>.
2. I. K. Herrmann, M. J. A. Wood, and G. Fuhrmann, "Extracellular Vesicles as a Next-Generation Drug Delivery Platform," *Nature Nanotechnology* 16, no. 7 (2021): 748–759, <https://doi.org/10.1038/s41565-021-00931-2>.
3. K. W. Witwer and J. Wolfram, "Extracellular Vesicles Versus Synthetic Nanoparticles for Drug Delivery," *Nature Reviews Materials* 6, no. 2 (2021): 103–106, <https://doi.org/10.1038/s41578-020-00277-6>.
4. A. Uzel, L. Agiotis, A. Baron, et al., "Single Pulse Nanosecond Laser-Stimulated Targeted Delivery of Anti-Cancer Drugs From Hybrid Lipid Nanoparticles Containing 5 nm Gold Nanoparticles," *Small* 19, no. 52 (2023): 2305591, <https://doi.org/10.1002/sml.202305591>.
5. S. Lou, W. Hu, P. Wei, et al., "Artificial Nanovesicles Derived From Cells: A Promising Alternative to Extracellular Vesicles," *ACS Applied Materials & Interfaces* 17, no. 1 (2025): 22–41, <https://doi.org/10.1021/acsmi.4c12567>.
6. T. Dauphin, L. de Beaurepaire, A. Salama, et al., "Scalability of Spheroid-Derived Small Extracellular Vesicles Production in Stirred Systems," *Frontiers in Bioengineering and Biotechnology* 13 (2025): 1516482, <https://doi.org/10.3389/fbioe.2025.1516482>.
7. F. Tan, X. Li, Z. Wang, J. Li, K. Shahzad, and J. Zheng, "Clinical Applications of Stem Cell-Derived Exosomes," *Signal Transduction and Targeted Therapy* 9, no. 1 (2024): 17, <https://doi.org/10.1038/s41392-023-01704-0>.
8. X. Wang, J. Xia, L. Yang, J. Dai, and L. He, "Recent Progress in Exosome Research: Isolation, Characterization and Clinical Applications," *Cancer Gene Therapy* 30, no. 8 (2023): 1051–1065, <https://doi.org/10.1038/s41417-023-00617-y>.
9. L. Liu, X. Bai, M.-V. Martikainen, et al., "Cell Membrane Coating Integrity Affects the Internalization Mechanism of Biomimetic Nanoparticles," *Nature Communications* 12, no. 1 (2021): 5726, <https://doi.org/10.1038/s41467-021-26052-x>.
10. V. Syromiatnikova, A. Prokopenko, and M. Gomzikova, "Methods of the Large-Scale Production of Extracellular Vesicles," *International Journal of Molecular Sciences* 23, no. 18 (2022): 10522, <https://doi.org/10.3390/ijms231810522>.
11. R. Molinaro, C. Corbo, J. O. Martinez, et al., "Biomimetic Proteolipid Vesicles for Targeting Inflamed Tissues," *Nature Materials* 15, no. 9 (2016): 1037–1046, <https://doi.org/10.1038/nmat4644>.
12. T. Einfalt, D. Witzigmann, C. Edlinger, et al., "Biomimetic Artificial Organelles With In Vitro and In Vivo Activity Triggered by Reduction in Microenvironment," *Nature Communications* 9, no. 1 (2018): 1127, <https://doi.org/10.1038/s41467-018-03560-x>.
13. Z. Qiao, K. Zhang, J. Liu, et al., "Biomimetic Electrodynamically Nanoparticles Comprising Ginger-Derived Extracellular Vesicles for Synergistic Anti-Infective Therapy," *Nature Communications* 13, no. 1 (2022): 7164, <https://doi.org/10.1038/s41467-022-34883-5>.
14. S. C. Jang, O. Y. Kim, C. M. Yoon, et al., "Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors," *ACS Nano* 7, no. 9 (2013): 7698–7710, <https://doi.org/10.1021/nn402232g>.
15. Y. Seo, H. Kang, and J. Park, "Shear Stress-Induced Influx of Extracellular Calcium Ions: A Pivotal Trigger Amplifying the Production of Mesenchymal Stem Cell-Derived Extracellular Vesicles," *Nanoscale* 17 (2025): 3861–3872, <https://doi.org/10.1039/D4NR01215A>.
16. H. Kang, Y. H. Bae, Y. Kwon, S. Kim, and J. Park, "Extracellular Vesicles Generated Using Bioreactors and Their Therapeutic Effect on the Acute Kidney Injury Model," *Advanced Healthcare Materials* 11, no. 4 (2022): 2101606, <https://doi.org/10.1002/adhm.202101606>.
17. W. Jo, D. Jeong, J. Kim, et al., "Microfluidic Fabrication of Cell-Derived Nanovesicles as Endogenous RNA Carriers," *Lab on a Chip* 14, no. 7 (2014): 1261–1269, <https://doi.org/10.1039/C3LC50993A>.
18. L. Rao, B. Cai, L.-L. Bu, et al., "Microfluidic Electroporation-Facilitated Synthesis of Erythrocyte Membrane-Coated Magnetic Nanoparticles for Enhanced Imaging-Guided Cancer Therapy," *ACS Nano* 11, no. 4 (2017): 3496–3505, <https://doi.org/10.1021/acsnano.7b00133>.
19. J. Yoon, W. Jo, D. Jeong, J. Kim, H. Jeong, and J. Park, "Generation of Nanovesicles With Sliced Cellular Membrane Fragments for Exogenous Material Delivery," *Biomaterials* 59 (2015): 12–20, <https://doi.org/10.1016/j.biomaterials.2015.04.028>.
20. E. Thouvenot, L. Charnay, N. Burshtein, et al., "High-Yield Bioproduction of Extracellular Vesicles From Stem Cell Spheroids via Millifluidic Vortex Transport," *Advanced Materials* 37, no. 20 (2025): 2412498, <https://doi.org/10.1002/adma.202412498>.
21. J. A. Peruzzi, T. F. Gunnels, H. I. Edelstein, et al., "Enhancing Extracellular Vesicle Cargo Loading and Functional Delivery by Engineering Protein-Lipid Interactions," *Nature Communications* 15, no. 1 (2024): 5618, <https://doi.org/10.1038/s41467-024-49678-z>.
22. M. Hasanzadeh Kafshgari and O. Hayden, "Advances in Analytical Microfluidic Workflows for Differential Cancer Diagnosis," *Nano Select* 4, no. 1 (2023): 1–47, <https://doi.org/10.1002/nano.202200158>.
23. A. D. Stroock, S. K. W. Dertinger, A. Ajdari, I. Mezic, H. A. Stone, and G. M. Whitesides, "Chaotic Mixer for Microchannels," *Science* 295, no. 5555 (2002): 647–651, <https://doi.org/10.1126/science.1066238>.
24. A. Rahmat, M. Barigou, and A. Alexiadis, "Deformation and Rupture of Compound Cells Under Shear: A Discrete Multiphysics Study," *Physics of Fluids* 31, no. 5 (2019), <https://doi.org/10.1063/1.5091999>.
25. S. Ebrahimi and P. Bagchi, "A Computational Study of Red Blood Cell Deformability Effect on Hemodynamic Alteration in Capillary Vessel Networks," *Scientific Reports* 12, no. 1 (2022): 4304, <https://doi.org/10.1038/s41598-022-08357-z>.
26. A. Nasiri Kenari, K. Kastaniegaard, D. W. Greening, et al., "Proteomic and Post-Translational Modification Profiling of Exosome-Mimetic Nanovesicles Compared to Exosomes," *Proteomics* 19, no. 8 (2019): 1800161, <https://doi.org/10.1002/pmic.201800161>.
27. F. Aliakbari, N. B. Stocck, M. Cole-André, et al., "A Methodological Primer of Extracellular Vesicles Isolation and Characterization via Different Techniques," *Biology Methods and Protocols* 9, no. 1 (2024): bpae009, <https://doi.org/10.1093/biomethods/bpae009>.
28. J. Kim, J. W. Hong, D. P. Kim, J. H. Shin, and I. Park, "Nanowire-Integrated Microfluidic Devices for Facile and Reagent-Free Mechanical Cell Lysis," *Lab on a Chip* 12, no. 16 (2012): 2914–2921, <https://doi.org/10.1039/C2LC40154A>.
29. K. Onwudiwe, J. Najera, L. Holen, et al., "Single-Cell Mechanical Assay Unveils Viscoelastic Similarities in Normal and Neoplastic Brain Cells," *Biophysical Journal* 123, no. 9 (2024): 1098–1105, <https://doi.org/10.1016/j.bpj.2024.03.034>.
30. D. Gonzalez-Rodriguez, L. Guillou, F. Cornat, et al., "Mechanical Criterion for the Rupture of a Cell Membrane Under Compression," *Biophysical Journal* 111, no. 12 (2016): 2711–2721, <https://doi.org/10.1016/j.bpj.2016.11.001>.
31. E. A. Zmievskaya, S. A. Mukhametshin, I. A. Ganeeva, et al., "Artificial Extracellular Vesicles Generated From T Cells Using Different Induction Techniques," *Biomedicine* 12, no. 4 (2024): 919, <https://doi.org/10.3390/biomedicine12040919>.

32. B. S. Joshi, D. Ortiz, and I. S. Zuhorn, "Converting Extracellular Vesicles Into Nanomedicine: Loading and Unloading of Cargo," *Materials Today Nano* 16 (2021): 100148, <https://doi.org/10.1016/j.mtnano.2021.100148>.
33. R. Liam-Or, F. N. Faruqu, A. Walters, et al., "Cellular Uptake and In Vivo Distribution of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles Are Protein Corona Dependent," *Nature Nanotechnology* 19, no. 6 (2024): 846–855, <https://doi.org/10.1038/s41565-023-01585-y>.
34. E. Á. Tóth, L. Turiák, T. Visnovitz, et al., "Formation of a Protein Corona on the Surface of Extracellular Vesicles in Blood Plasma," *Journal of Extracellular Vesicles* 10, no. 11 (2021): 12140, <https://doi.org/10.1002/jev2.12140>.
35. C. Werner, S. Stangl, L. Salvermoser, et al., "Hsp70 in Liquid Biopsies—A Tumor-Specific Biomarker for Detection and Response Monitoring in Cancer," *Cancers* 13, no. 15 (2021): 3706, <https://doi.org/10.3390/cancers13153706>.
36. C. Yang, J. Han, H. Liu, et al., "Storage of Plasma-Derived Exosomes: Evaluation of Anticoagulant Use and Preserving Temperatures," *Platelets* 35, no. 1 (2024): 2337255, <https://doi.org/10.1080/09537104.2024.2337255>.
37. S. Sivori, P. Vacca, G. Del Zotto, E. Munari, M. C. Mingari, and L. Moretta, "Human NK Cells: Surface Receptors, Inhibitory Checkpoints, and Translational Applications," *Cellular & Molecular Immunology* 16, no. 5 (2019): 430–441, <https://doi.org/10.1038/s41423-019-0206-4>.
38. H. J. Pegram, D. M. Andrews, M. J. Smyth, P. K. Darcy, and M. H. Kershaw, "Activating and Inhibitory Receptors of Natural Killer Cells," *Immunology & Cell Biology* 89, no. 2 (2011): 216–224, <https://doi.org/10.1038/icc.2010.78>.
39. L. Dietz, J. Oberländer, A. Mateos-Maroto, et al., "Uptake of Extracellular Vesicles Into Immune Cells is Enhanced by the Protein Corona," *Journal of Extracellular Vesicles* 12, no. 12 (2023): 12399, <https://doi.org/10.1002/jev2.12399>.
40. K. Chaudhry, A. Geiger, E. Dowlati, et al., "Co-Transducing B7H3 CAR-NK Cells With the DNR Preserves Their Cytolytic Function Against GBM in the Presence of Exogenous TGF- β ," *Molecular Therapy—Methods & Clinical Development* 27 (2022): 415–430, <https://doi.org/10.1016/j.omtm.2022.10.010>.
41. B. Hei, R.-E. Liu, and M. Li, "Ursolic Acid Inhibits Glioblastoma Through Suppressing TGF β -Mediated Epithelial-Mesenchymal Transition (EMT) and Angiogenesis," *Heliyon* 10, no. 6 (2024): e27722, <https://doi.org/10.1016/j.heliyon.2024.e27722>.
42. T. L. Whiteside, "Immune Modulation of T-Cell and NK (Natural Killer) Cell Activities by TEXs (Tumour-Derived Exosomes)," *Biochemical Society Transactions* 41, no. 1 (2013): 245–251, <https://doi.org/10.1042/BST20120265>.
43. G. Berchem, M. Z. Noman, M. Bosseler, et al., "Hypoxic Tumor-Derived Microvesicles Negatively Regulate NK Cell Function by a Mechanism Involving TGF- β and miR23a Transfer," *Oncoimmunology* 5, no. 4 (2016): 1062968, <https://doi.org/10.1080/2162402X.2015.1062968>.
44. K. Krzewski, A. Gil-Krzewska, V. Nguyen, G. Peruzzi, and J. E. Coligan, "LAMP1/CD107a is Required for Efficient Perforin Delivery to Lytic Granules and NK-Cell Cytotoxicity," *Blood* 121, no. 23 (2013): 4672–4683, <https://doi.org/10.1182/blood-2012-08-453738>.
45. M. Yazdi, M. Hasanzadeh Kafshgari, and F. Khademi Moghadam, "Crosstalk Between Nk Cell Receptors and Tumor Membrane hsp70-Derived Peptide: A Combined Computational and Experimental Study," *Advanced Science* 11, no. 14 (2024): 2305998, <https://doi.org/10.1002/advs.202305998>.
46. E. Vulpis, L. Loconte, A. Peri, et al., "Impact on NK Cell Functions of Acute Versus Chronic Exposure to Extracellular Vesicle-Associated MICA: Dual Role in Cancer Immunosurveillance," *Journal of Extracellular Vesicle* 11 (2022): 12176, <https://doi.org/10.1002/jev2.12176>.
47. T. Deuse, X. Hu, S. Agbor-Enoh, et al., "The SIRP α -CD47 Immune Checkpoint in NK Cells," *Journal of Experimental Medicine* 218, no. 3 (2021): 20200839, <https://doi.org/10.1084/jem.20200839>.
48. I. Dean, C. Y. C. Lee, Z. K. Tuong, et al., "Rapid Functional Impairment of Natural Killer Cells Following Tumor Entry Limits Anti-Tumor Immunity," *Nature Communications* 15, no. 1 (2024): 683, <https://doi.org/10.1038/s41467-024-44789-z>.
49. Z. Chen, P. Zhao, Z. Luo, et al., "Cancer Cell Membrane–Biomimetic Nanoparticles for Homologous-Targeting Dual-Modal Imaging and Photothermal Therapy," *ACS Nano* 10, no. 11 (2016): 10049–10057, <https://doi.org/10.1021/acsnano.6b04695>.
50. J.-Y. Zhu, D.-W. Zheng, M.-K. Zhang, et al., "Preferential Cancer Cell Self-Recognition and Tumor Self-Targeting by Coating Nanoparticles With Homotypic Cancer Cell Membranes," *Nano Letters* 16, no. 9 (2016): 5895–5901, <https://doi.org/10.1021/acs.nanolett.6b02786>.
51. L. Qiao, S. Hu, K. Huang, et al., "Tumor Cell-Derived Exosomes Home to Their Cells of Origin and Can be Used as Trojan Horses to Deliver Cancer Drugs," *Theranostics* 10, no. 8 (2020): 3474–3487, <https://doi.org/10.7150/thno.39434>.
52. T. Tian, Y.-L. Zhu, Y.-Y. Zhou, et al., "Exosome Uptake Through Clathrin-Mediated Endocytosis and Macropinocytosis and Mediating miR-21 Delivery," *Journal of Biological Chemistry* 289, no. 32 (2014): 22258–22267, <https://doi.org/10.1074/jbc.M114.588046>.
53. S. Mazumdar, D. Chitkara, and A. Mittal, "Exploration and Insights Into the Cellular Internalization and Intracellular Fate of Amphiphilic Polymeric Nanocarriers," *Acta Pharmaceutica Sinica B* 11, no. 4 (2021): 903–924, <https://doi.org/10.1016/j.apsb.2021.02.019>.
54. N. Anastasov, I. Höfig, V. Radulovic, et al., "A 3D-microtissue-Based Phenotypic Screening of Radiation Resistant Tumor Cells With Synchronized Chemotherapeutic Treatment," *BMC Cancer* 15 (2015): 466, <https://doi.org/10.1186/s12885-015-1481-9>.
55. Y. Tian, M. Gong, Y. Hu, et al., "Quality and Efficiency Assessment of Six Extracellular Vesicle Isolation Methods by Nano-Flow Cytometry," *Journal of Extracellular Vesicles* 9, no. 1 (2020): 1697028, <https://doi.org/10.1080/20013078.2019.1697028>.
56. R. J. Lobb, M. Becker, S. Wen Wen, et al., "Optimized Exosome Isolation Protocol for Cell Culture Supernatant and human Plasma," *Journal of Extracellular Vesicles* 4, no. 1 (2015): 27031, <https://doi.org/10.3402/jev.v4.27031>.
57. H. Guo, E. Franken, Y. Deng, et al., "Electron-Event Representation Data Enable Efficient cryoEM File Storage With Full Preservation of Spatial and Temporal Resolution," *IUCr* 7, no. Pt 5 (2020): 860–869, <https://doi.org/10.1107/s205225252000929x>.
58. F. Grollios, H. Kohr, J. O. O. Espinoza, and E. Pryor, "Thermo Scientific Smart EPU: Towards the "One-Button" Screening Solution," *Microscopy and Microanalysis* 30 (2024): ozae044386, <https://doi.org/10.1093/mam/ozae044.386>.
59. A. Punjani, J. L. Rubinstein, D. J. Fleet, and M. A. Brubaker, "cryoSPARC: Algorithms for Rapid Unsupervised Cryo-EM Structure Determination," *Nature Methods* 14, no. 3 (2017): 290–296, <https://doi.org/10.1038/nmeth.4169>.
60. M. Sousa de Almeida, E. Susnik, B. Drasler, P. Taladriz-Blanco, A. Petri-Fink, and B. Rothen-Rutishauser, "Understanding Nanoparticle Endocytosis to Improve Targeting Strategies in Nanomedicine," *Chemical Society Reviews* 50, no. 9 (2021): 5397–5434, <https://doi.org/10.1039/d0cs01127d>.
61. M. Hasanzadeh Kafshgari, F. J. Harding, and N. H. Voelcker, "Insights Into Cellular Uptake of Nanoparticles," *Current Drug Delivery* 12, no. 1 (2015): 63–77, <https://doi.org/10.2174/1567201811666140821110631>.
62. B. Alkotub, L. Bauer, A. Bashiri Dezfouli, et al., "Radiosensitizing Capacity of Fenofibrate in Glioblastoma Cells Depends on Lipid Metabolism," *Redox Biology* 79 (2025): 103452, <https://doi.org/10.1016/j.redox.2024.103452>.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.

Supporting File 1: adma72240-sup-0001-SuppMat.pdf.

Supporting File 2: adma72240-sup-0002-MoviesS1.mp4.

Supporting File 3: adma72240-sup-0003-MoviesS2.mp4.

Supporting File 4: adma72240-sup-0004-MoviesS3.mp4.

Supporting File 5: adma72240-sup-0005-MoviesS4.mp4.

Supporting File 6: adma72240-sup-0006-MoviesS5.mp4.

Supporting File 7: adma72240-sup-0007-MoviesS6.mp4.

Supporting File 8: adma72240-sup-0008-MoviesS7.mp4.